<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://ajpendo.physiology.org">
<title>AJP: Endocrinology and Metabolism recent issues</title>
<link>http://ajpendo.physiology.org</link>
<description>AJP: Endocrinology and Metabolism RSS feed -- recent issues</description>
<prism:eIssn>1522-1555</prism:eIssn>
<prism:publicationName>AJP: Endocrinology and Metabolism</prism:publicationName>
<prism:issn>0193-1849</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1235?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/full/297/6/E1237?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1238?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1247?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1260?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1269?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1276?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1283?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1291?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1304?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1313?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1324?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1331?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1339?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1349?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1358?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1366?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1378?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1388?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1395?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1414?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1420?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/full/297/5/E975?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E977?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E987?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E999?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1004?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1013?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1023?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1030?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1039?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1046?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1056?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1067?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1078?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1089?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1097?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1105?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1115?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1125?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1137?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1147?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1154?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1162?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1171?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1179?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1187?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1197?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1205?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1212?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1222?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/full/297/5/E1233?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://ajpendo.physiology.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://ajpendo.physiology.org/icons/banner/title.gif">
<title>AJP: Endocrinology and Metabolism</title>
<url>http://ajpendo.physiology.org/icons/banner/title.gif</url>
<link>http://ajpendo.physiology.org</link>
</image>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1235?rss=1">
<title><![CDATA[Follicular origins of modern reproductive endocrinology]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1235?rss=1</link>
<description><![CDATA[
<p>This essay looks at the historical significance of the APS Classic Paper: <b>Allen E, Doisy EA.</b> The induction of a sexually mature condition in immature females by injection of the ovarian follicular hormone. <I>Am J Physiol</I> 69: 577&ndash;588, 1924 (<inter-ref locator="http://ajplegacy.physiology.org/cgi/reprint/69/3/577" locator-type="url">http://ajplegacy.physiology.org/cgi/reprint/69/3/577</inter-ref>).</p>
]]></description>
<dc:creator><![CDATA[Stephens, S. M., Moley, K. H.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:17 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00575.2009</dc:identifier>
<dc:title><![CDATA[Follicular origins of modern reproductive endocrinology]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1236</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1235</prism:startingPage>
<prism:section>Essays on APS Classic Papers</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/full/297/6/E1237?rss=1">
<title><![CDATA[The search for the membrane thyroid hormone receptor]]></title>
<link>http://ajpendo.physiology.org/cgi/content/full/297/6/E1237?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Samson, W. K.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:17 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00502.2009</dc:identifier>
<dc:title><![CDATA[The search for the membrane thyroid hormone receptor]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1237</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1237</prism:startingPage>
<prism:section>Editorial Focus</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1238?rss=1">
<title><![CDATA[Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1238?rss=1</link>
<description><![CDATA[
<p>A thyroid hormone receptor on integrin v&beta;3 that mediates cell surface-initiated nongenomic actions of thyroid hormone on tumor cell proliferation and on angiogenesis has been described. Transduction of the hormone signal into these recently recognized proliferative effects is by extracellular-regulated kinases 1/2 (ERK1/2). Other nongenomic actions of the hormone may be transduced by phosphatidylinositol 3-kinase (PI3K) and are initiated in cytoplasm or at the cell surface. PI3K-mediated effects are important to angiogenesis or other recently appreciated cell functions but apparently not to tumor cell division. For those actions of thyroid hormone [<scp>l</scp>-thyroxine (T<SUB>4</SUB>) and 3,3'-5-triiodo-<scp>l</scp>-thyronine (T<SUB>3</SUB>)] that begin at the integrin receptor, tetraiodothyroacetic acid (tetrac) is an inhibitor of and probe for the participation of the receptor in downstream intracellular events. In addition, tetrac has actions initiated at the integrin receptor that are unrelated to inhibition of the effects of T<SUB>4</SUB> and T<SUB>3</SUB> but do involve gene transcription in tumor cells. Discussed here are the implications of translating these nongenomic mechanisms of thyroid hormone analogs into clinical cancer cell biology, tumor-related angiogenesis, and modulation of angiogenesis that is not related to cancer.</p>
]]></description>
<dc:creator><![CDATA[Davis, P. J., Davis, F. B., Lin, H.-Y., Mousa, S. A., Zhou, M., Luidens, M. K.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:17 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00480.2009</dc:identifier>
<dc:title><![CDATA[Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1246</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1238</prism:startingPage>
<prism:section>2009 Solomon Berson Award Lecture</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1247?rss=1">
<title><![CDATA[Recent advances in understanding leptin signaling and leptin resistance]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1247?rss=1</link>
<description><![CDATA[
<p>The brain controls energy homeostasis and body weight by integrating various metabolic signals. Leptin, an adipose-derived hormone, conveys critical information about peripheral energy storage and availability to the brain. Leptin decreases body weight by both suppressing appetite and promoting energy expenditure. Leptin directly targets hypothalamic neurons, including AgRP and POMC neurons. These leptin-responsive neurons widely connect to other neurons in the brain, forming a sophisticated neurocircuitry that controls energy intake and expenditure. The anorexigenic actions of leptin are mediated by LEPRb, the long form of the leptin receptor, in the hypothalamus. LEPRb activates both JAK2-dependent and -independent pathways, including the STAT3, PI 3-kinase, MAPK, AMPK, and mTOR pathways. These pathways act coordinately to form a network that fully mediates leptin response. LEPRb signaling is regulated by both positive (e.g., SH2B1) and negative (e.g., SOCS3 and PTP1B) regulators and by endoplasmic reticulum stress. Leptin resistance, a primary risk factor for obesity, likely results from impairment in leptin transport, LEPRb signaling, and/or the neurocircuitry of energy balance.</p>
]]></description>
<dc:creator><![CDATA[Morris, D. L., Rui, L.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:17 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00274.2009</dc:identifier>
<dc:title><![CDATA[Recent advances in understanding leptin signaling and leptin resistance]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1259</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1247</prism:startingPage>
<prism:section>Reviews</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1260?rss=1">
<title><![CDATA[Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young healthy people]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1260?rss=1</link>
<description><![CDATA[
<p>Glucocorticoids cause muscle atrophy and weakness, but the mechanisms for these effects are unclear. The purpose of this study was to test a hypothesis that prednisone (Pred) counteracts insulin's anabolic effects on muscle. A randomized, double-blind cross-over design was used to test the effects of 6 days either Pred (0.8 mg&middot;kg<sup>&ndash;1</sup>&middot;day<sup>&ndash;1</sup>) or placebo use in seven healthy young volunteers. Protein dynamics were measured across the leg using stable isotope tracers of leucine (Leu) and phenylalanine (Phe) after overnight fast and during a hyperinsulinemic (1.5 &micro;U&middot;min<sup>&ndash;1</sup>&middot;kg FFM<sup>&ndash;1</sup>) euglycemic clamp with amino acid replacement. Fasting glucose, amino acids, insulin, and glucagon were higher (<I>P</I> &lt; 0.01) on Pred vs. placebo, whereas leg blood flow was 18% lower. However, basal whole body and leg kinetics of Leu and Phe were unaltered by Pred. Insulin infusion increased leg glucose uptake in both trials but was 65% lower with Pred than with placebo. Insulin in both trials similarly suppressed whole body flux of Leu and Phe. Importantly, insulin increased net Leu and Phe balance across the leg and the balance between muscle protein synthesis and breakdown, but these changes were 45&ndash;140% lower (<I>P</I> &lt; 0.03) in Pred than in placebo. The present study demonstrates that short-term Pred use in healthy people does not alter whole body or leg muscle protein metabolism during the postaborptive state but causes muscle insulin resistance for both glucose and amino acid metabolism, with a blunted protein anabolism. This interactive effect may lead to muscle atrophy with continued use of glucocorticoids.</p>
]]></description>
<dc:creator><![CDATA[Short, K. R., Bigelow, M. L., Nair, K. S.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:17 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00345.2009</dc:identifier>
<dc:title><![CDATA[Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young healthy people]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1268</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1260</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1269?rss=1">
<title><![CDATA[Regulation of food intake and body weight by recombinant proghrelin]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1269?rss=1</link>
<description><![CDATA[
<p>Ghrelin is a 28-amino-acid hormone derived from the endoproteolytic processing of its prehormone proghrelin. Although ghrelin has been reported to regulate food intake and body weight, it is still unknown whether proghrelin exercises any biological function. Here we show that recombinant proghrelin alters food intake and energy metabolism in mice. After intraperitoneal administration of recombinant proghrelin (100 nmol/kg body wt), cumulative food intake was significantly increased at <I>days 1</I>, <I>2</I>, and <I>3</I> (6 &plusmn; 0.3, 13 &plusmn; 0.5, and 20 &plusmn; 0.8 g vs. 5 &plusmn; 0.2, 10 &plusmn; 0.2, and 16 &plusmn; 0.3 g of the control mice receiving normal saline, respectively, <I>n</I> = 6, <I>P</I> &lt; 0.05). Twelve-hour cumulative food intake in the light photo period in mice treated with proghrelin increased significantly relative to the control (2.1 &plusmn; 0.04 vs. 1.3 &plusmn; 0.2 g, <I>n</I> = 6, <I>P</I> &lt; 0.05). No change in 12-h cumulative food intake in the dark photo period was observed between mice treated with proghrelin and vehicle (4.2 &plusmn; 0.6 vs. 4.3 &plusmn; 0.6 g, <I>n</I> = 6, <I>P</I> &gt; 0.05). This is associated with a decrease in body weight (0.42 &plusmn; 0.04 g) for mice treated with proghrelin, whereas control animals gained body weight (0.31 &plusmn; 0.04 g). Mice treated with proghrelin demonstrate a significant decrease in respiratory quotient, indicating an increase in fat consumption. Recombinant proghrelin is functionally active with effects on food intake and energy metabolism.</p>
]]></description>
<dc:creator><![CDATA[Zhang, W., Majumder, A., Wu, X., Mulholland, M. W.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:17 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00337.2009</dc:identifier>
<dc:title><![CDATA[Regulation of food intake and body weight by recombinant proghrelin]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1275</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1269</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1276?rss=1">
<title><![CDATA[A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1276?rss=1</link>
<description><![CDATA[
<p>Platelet-activating factor (PAF) and lysophosphatidylcholine (LPC) are potent inflammatory lipids. Elevated levels of PAF and LPC are associated with the onset of diabetic retinopathy and neurodegeneration. However, the molecular mechanisms underlying such defects remain elusive. LPCAT1 is a newly reported lysophospholipid acyltransferase implicated in the anti-inflammatory response by its role in conversion of LPC to PC. Intriguingly, the LPCAT1 enzyme also catalyzes the synthesis of PAF from lyso-PAF with use of acetyl-CoA as a substrate. The present studies investigated regulatory roles of LPCAT1 in the synthesis of inflammatory lipids during the onset of diabetes. Our work shows that LPCAT1 plays an important role in the inactivation of PAF by catalyzing the synthesis of alkyl-PC, an inactivated form of PAF with use of acyl-CoA and lyso-PAF as substrates. In support of a role of LPCAT1 in anti-inflammatory responses in diabetic retinopathy, LPCAT1 is most abundantly expressed in the retina. Moreover, LPCAT1 mRNA levels and acyltransferase activity toward lyso-PAF and LPC were significantly downregulated in retina and brain tissues in response to the onset of diabetes in <I>Ins2</I><sup><I>Akita</I></sup> and <I>db/db</I> mice, mouse models of type 1 and type 2 diabetes, respectively. Conversely, treatment of <I>db/db</I> mice with rosiglitazone, an antidiabetes compound, significantly upregulated LPCAT1 mRNA levels concurrently with increased acyltransferase activity in the retina and brain. Collectively, these findings identified a novel regulatory role of LPCAT1 in catalyzing the inactivation of inflammatory lipids in the retina of diabetic mice.</p>
]]></description>
<dc:creator><![CDATA[Cheng, L., Han, X., Shi, Y.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:17 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00475.2009</dc:identifier>
<dc:title><![CDATA[A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1282</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1276</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1283?rss=1">
<title><![CDATA[USP19-deubiquitinating enzyme regulates levels of major myofibrillar proteins in L6 muscle cells]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1283?rss=1</link>
<description><![CDATA[
<p>The ubiquitin-proteasome system plays an important role in the degradation of myofibrillar proteins that occurs in muscle wasting. Many studies have demonstrated the importance of enzymes mediating conjugation of ubiquitin. However, little is known about the role of deubiquitinating enzymes. We previously showed that the USP19-deubiquitinating enzyme is induced in atrophying skeletal muscle (Combaret L, Adegoke OA, Bedard N, Baracos V, Attaix D, Wing SS. <I>Am J Physiol Endocrinol Metab</I> 288: E693&ndash;E700, 2005). To further explore the role of USP19, we used small interfering RNA (siRNA) in L6 muscle cells. Lowering USP19 by 70&ndash;90% in myotubes resulted in a 20% decrease in the rate of proteolysis and an 18% decrease in the rate of protein synthesis, with no net change in protein content. Despite the decrease in overall synthesis, there were ~1.5-fold increases in protein levels of myosin heavy chain (MHC), actin, and troponin T and a ~2.5-fold increase in tropomyosin. USP19 depletion also increased MHC and tropomyosin mRNA levels, suggesting that this effect is due to increased transcription. Consistent with this, USP19 depletion increased myogenin protein and mRNA levels approximately twofold. Lowering myogenin using siRNA prevented the increase in MHC and tropomyosin upon USP19 depletion, indicating that myogenin mediated the increase in myofibrillar proteins. Dexamethasone treatment lowered MHC and increased USP19. Depletion of USP19 reversed the dexamethasone suppression of MHC. These studies demonstrate that USP19 modulates transcription of major myofibrillar proteins and indicate that the ubiquitin system not only mediates the increased protein breakdown but is also involved in the decreased protein synthesis in atrophying skeletal muscle.</p>
]]></description>
<dc:creator><![CDATA[Sundaram, P., Pang, Z., Miao, M., Yu, L., Wing, S. S.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:17 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00409.2009</dc:identifier>
<dc:title><![CDATA[USP19-deubiquitinating enzyme regulates levels of major myofibrillar proteins in L6 muscle cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1290</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1283</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1291?rss=1">
<title><![CDATA[Different impacts of saturated and unsaturated free fatty acids on COX-2 expression in C2C12 myotubes]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1291?rss=1</link>
<description><![CDATA[
<p>In skeletal muscle, saturated free fatty acids (FFAs) act as proinflammatory stimuli, and cyclooxygenase-2 (COX-2) is a pro/anti-inflammatory enzyme induced at sites of inflammation, which contributes to prostaglandin production. However, little is known about the regulation of COX-2 expression and its responses to FFAs in skeletal muscle. Herein, we examined the effects of saturated and unsaturated FFAs, including a recently identified lipokine (lipid hormone derived from adipocytes), palmitoleate, on COX-2 expression in C<SUB>2</SUB>C<SUB>12</SUB> myotubes as a skeletal muscle model. Exposure of myotubes to saturated FFAs [palmitate (16:0) and stearate (18:0)], but not to unsaturated FFAs [palmitoleate (16:1), oleate (18:1), and linoleate (18:2)], led to a slow-onset induction of COX-2 expression and subsequent prostaglandin E<SUB>2</SUB> production via mechanisms involving the p38 MAPK and NF-B but not the PKC signaling cascades. Pharmacological modulation of mitochondrial oxidative function failed to interfere with COX-2 expression, suggesting the mitochondrial overload/excessive &beta;-oxidation contribution to this event to be minimal. On the contrary, unsaturated FFAs appeared to effectively antagonize palmitate-induced COX-2 expression with markedly different potencies (linoleate &gt; oleate &gt; palmitoleate), being highly associated with the suppressive profile of each unsaturated FFA toward palmitate-evoked intracellular signals, including p38, JNK, ERK1/2 MAPKs, and PKC, as well as IB degradation. In addition, our data suggest little involvement of PPAR in the protective actions of unsaturated FFAs against palmitate-induced COX-2 expression. No direct contribution of the increased COX-2 activity in generating palmitate-induced insulin resistance was detected, at least in terms of insulin-responsive Akt phosphorylation and GLUT4 translocation. Taken together, our data provide a novel insight into the molecular mechanisms responsible for the FFA-induced COX-2 expression in skeletal muscle and raise the possibility that, in skeletal myocytes, COX-2 and its product prostaglandins may play an important role in the complex inflammation responses caused by elevated FFAs, for example, in the diabetic state.</p>
]]></description>
<dc:creator><![CDATA[Kadotani, A., Tsuchiya, Y., Hatakeyama, H., Katagiri, H., Kanzaki, M.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00293.2009</dc:identifier>
<dc:title><![CDATA[Different impacts of saturated and unsaturated free fatty acids on COX-2 expression in C2C12 myotubes]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1303</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1291</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1304?rss=1">
<title><![CDATA[Deletion of Fas in the pancreatic {beta}-cells leads to enhanced insulin secretion]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1304?rss=1</link>
<description><![CDATA[
<p>Fas/Fas ligand belongs to the tumor necrosis factor superfamily of receptors/ligands and is best known for its role in apoptosis. However, recent evidence supports its role in other cellular responses, including proliferation and survival. Although Fas has been implicated as an essential mediator of &beta;-cell death in the pathogenesis of type 1 diabetes, the essential role of Fas specifically in pancreatic &beta;-cells has been found to be controversial. Moreover, the role of Fas on &beta;-cell homeostasis and function is not clear. The objective of this study is to determine the role of Fas specifically in &beta;-cells under both physiological and diabetes models. Mice with Fas deletion specifically in the &beta;-cells were generated using the Cre-loxP system. Cre-mediated Fas deletion was under the control of the rat insulin promoter. Absence of Fas in &beta;-cells leads to complete protection against FasL-induced cell death. However, Fas is not essential in determining &beta;-cell mass or susceptibility to streptozotocin- or HFD-induced diabetes. Importantly, Fas deletion in &beta;-cells leads to increased p65 expression, enhanced glucose tolerance, and glucose-stimulated insulin secretion, with increased exocytosis as manifested by increased changes in membrane capacitance and increased expression of Syntaxin1A, VAMP2, and munc18a. Together, our study shows that Fas in the &beta;-cells indeed plays an essential role in the canonical death receptor-mediated apoptosis but is not essential in regulating &beta;-cell mass or diabetes development. However, &beta;-cell Fas is critical in the regulation of glucose homeostasis through regulation of the exocytosis machinery.</p>
]]></description>
<dc:creator><![CDATA[Choi, D., Radziszewska, A., Schroer, S. A., Liadis, N., Liu, Y., Zhang, Y., Lam, P. P. L., Sheu, L., Hao, Z., Gaisano, H. Y., Woo, M.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00217.2009</dc:identifier>
<dc:title><![CDATA[Deletion of Fas in the pancreatic {beta}-cells leads to enhanced insulin secretion]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1312</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1304</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1313?rss=1">
<title><![CDATA[mTOR, AMPK, and GCN2 coordinate the adaptation of hepatic energy metabolic pathways in response to protein intake in the rat]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1313?rss=1</link>
<description><![CDATA[
<p>Three transduction pathways are involved in amino acid (AA) sensing in liver: mammalian target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), and general control nondepressible kinase 2 (GCN2). However, no study has investigated the involvement of these signaling pathways in hepatic AA sensing. To address the question of liver AA sensing and signaling in response to a high-protein (HP) dietary supply, we investigated the changes in the phosphorylation state of hepatic mTOR (p-mTOR), AMPK (p-AMPK), and GCN2 (p-GCN2) by Western blotting. In rats fed a HP diet for 14 days, the hepatic p-AMPK and p-GCN2 were lower (<I>P</I> &lt; 0.001), and those of both the p-mTOR and eukaryotic initiation factor 4E-binding protein-1 phosphorylation (p-4E-BP1) were higher (<I>P</I> &lt; 0.01) compared with rats receiving a normal protein (NP) diet. In hepatocytes in primary culture, high AA concentration decreased AMPK phosphorylation whether insulin was present or not (<I>P</I> &lt; 0.01). Either AAs or insulin can stimulate p-mTOR, but this is not sufficient for 4E-BP1 phosphorylation that requires both (<I>P</I> &lt; 0.01). As expected, branched-chain AAs (BCAA) or leucine stimulated the phosphorylation of mTOR, but both insulin and BCAA or leucine are required for 4E-BP1 phosphorylation. GCN2 phosphorylation was reduced by both AAs and insulin(<I>P</I> &lt; 0.01), suggesting for the first time that the translation inhibitor GCN2 senses not only the AA deficiency but also the AA increase in the liver. The present findings demonstrate that AAs and insulin exert a coordinated action on translation and involved mTOR, AMPK, and GCN2 transduction pathways.</p>
]]></description>
<dc:creator><![CDATA[Chotechuang, N., Azzout-Marniche, D., Bos, C., Chaumontet, C., Gausseres, N., Steiler, T., Gaudichon, C., Tome, D.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.91000.2008</dc:identifier>
<dc:title><![CDATA[mTOR, AMPK, and GCN2 coordinate the adaptation of hepatic energy metabolic pathways in response to protein intake in the rat]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1323</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1313</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1324?rss=1">
<title><![CDATA[VLDL-TG kinetics: a dual isotope study for quantifying VLDL-TG pool size, production rates, and fractional oxidation in humans]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1324?rss=1</link>
<description><![CDATA[
<p>Very-low-density lipoproteins (VLDLs) are large, complex particles containing both surface proteins (e.g., ApoB100) and core lipids, e.g., cholesterol and triglycerides (TG). Whereas ApoB100 kinetics have been thoroughly studied, accurate measurement of VLDL-TG kinetics have proven difficult due to either complex mathematics or laborious procedures. The present study was therefore designed to measure VLDL-TG kinetics by dual isotope ex vivo labeled VLDL-TG tracers and well-established kinetics equations (bolus injection or the primed continuous infusion). Ten healthy Caucasian men [age, 23 &plusmn; 3 yr old (mean &plusmn; SD); body mass index, 24.7 &plusmn; 1.3 kg/m<sup>2</sup>] were included in the study. VLDL-TG rate of appearance (Ra) was measured using a dual-tracer technique ([9,10-<sup>3</sup>H]-labeled VLDL-TG and [1-<sup>14</sup>C]-labeled VLDL-TG) to allow comparison of various bolus decay curve fits with the Ra obtained by the primed continuous infusion (PCI; considered the gold standard). In addition, VLDL-TG fatty acid oxidation was measured as <sup>14</sup>CO<SUB>2</SUB> in exhaled breath, using the hyamine trapping technique. Following a bolus injection, tracer decay was better described by a biexponential than a monoexponential fit (<I>r</I><sup>2</sup> = 0.99 &plusmn; 0.01 vs. 0.97 &plusmn; 0.04, respectively, <I>P</I> = 0.01). VLDL-TG Ra calculated using the PCI correlated significantly with the biexponential fit ( = 0.62, <I>P</I> &lt; 0.05), whereas this was not the case for the monoexponential fit ( = &ndash;0.18, <I>P</I> = not significant). VLDL-TG Ra using the best fit of the bolus injection method (biexponential) was less than values obtained by the constant infusion technique [biexponential, 34.3 (range, 27.1&ndash;69.6) vs. PCI, 44.4 (range, 33.0&ndash;72.7), <I>P</I> &lt; 0.05]. Fractional oxidation of VLDL-TG was 37.2 &plusmn; 8.8% at 240 min corresponding to 198.8 &plusmn; 55.9 kcal/day or 10.6 &plusmn; 3.3% of resting energy expenditure (REE). Our data demonstrate that VLDL-TG Ra measured by a biexponential fit to a bolus decay curve correlates well with VLDL-TG Ra measured by a primed continuous infusion, and therefore that a "second" peripheral VLDL-TG compartment with rapid exchange of TG exists. VLDL-TG volume of distribution is therefore greater than previously anticipated. Finally our data supports that VLDL-TG contributes quantitatively to REE.</p>
]]></description>
<dc:creator><![CDATA[Sorensen, L. P., Gormsen, L. C., Nielsen, S.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00366.2009</dc:identifier>
<dc:title><![CDATA[VLDL-TG kinetics: a dual isotope study for quantifying VLDL-TG pool size, production rates, and fractional oxidation in humans]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1330</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1324</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1331?rss=1">
<title><![CDATA[Quantification of pancreatic islet distribution in situ in mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1331?rss=1</link>
<description><![CDATA[
<p>Tracing changes of specific cell populations in health and disease is an important goal of biomedical research. Precisely monitoring pancreatic &beta;-cell proliferation and islet growth is a challenging area of research. We have developed a method to capture the distribution of &beta;-cells in the intact pancreas of transgenic mice with fluorescence-tagged &beta;-cells with a macro written for ImageJ (rsb.info.nih.gov/ij/). Total &beta;-cell area and islet number and size distribution are quantified with reference to specific parameters and location for each islet and for small clusters of &beta;-cells. The entire distribution of islets can now be plotted in three dimensions, and the information from the distribution on the size and shape of each islet allows a quantitative and a qualitative comparison of changes in overall &beta;-cell area at a glance.</p>
]]></description>
<dc:creator><![CDATA[Kilimnik, G., Kim, A., Jo, J., Miller, K., Hara, M.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00479.2009</dc:identifier>
<dc:title><![CDATA[Quantification of pancreatic islet distribution in situ in mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1338</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1331</prism:startingPage>
<prism:section>Innovative Methodology</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1339?rss=1">
<title><![CDATA[Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1339?rss=1</link>
<description><![CDATA[
<p>C-type natriuretic peptide (CNP) plays a critical role in endochondral ossification through guanylyl cyclase-B (GC-B), a natriuretic peptide receptor subtype. Cartilage-specific overexpression of CNP enhances skeletal growth and rescues the dwarfism in a transgenic achondroplasia model with constitutive active mutation of fibroblast growth factor receptor-3. For future clinical application, the efficacy of CNP administration on skeletal growth must be evaluated. Due to the high clearance of CNP, maintaining a high concentration is technically difficult. However, to model high blood CNP concentration, we established a liver-targeted CNP-overexpressing transgenic mouse (SAP-CNP tgm). SAP-CNP tgm exhibited skeletal overgrowth in proportion to the blood CNP concentration and revealed phenotypes of systemic stimulation of cartilage bones, including limbs, paws, costal bones, spine, and skull. Furthermore, in SAP-CNP tgm, the size of the foramen magnum, the insufficient formation of which results in cervico-medullary compression in achondroplasia, also showed significant increase. CNP primarily activates GC-B, but under high concentrations it cross-reacts with guanylyl cyclase-A (GC-A), a natriuretic peptide receptor subtype of atrial natriuretic peptides (ANP) and brain natriuretic peptides (BNP). Although activation of GC-A could alter cardiovascular homeostasis, leading to hypotension and heart weight reduction, the skeletal overgrowth phenotype in the line of SAP-CNP tgm with mild overexpression of CNP did not accompany decrease of systolic blood pressure or heart weight. These results suggest that CNP administration stimulates skeletal growth without adverse cardiovascular effect, and thus CNP could be a promising remedy targeting achondroplasia.</p>
]]></description>
<dc:creator><![CDATA[Kake, T., Kitamura, H., Adachi, Y., Yoshioka, T., Watanabe, T., Matsushita, H., Fujii, T., Kondo, E., Tachibe, T., Kawase, Y., Jishage, K.-i., Yasoda, A., Mukoyama, M., Nakao, K.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00272.2009</dc:identifier>
<dc:title><![CDATA[Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1348</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1339</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1349?rss=1">
<title><![CDATA[Changed mitochondrial function by pre- and/or postpartum diet alterations in sheep]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1349?rss=1</link>
<description><![CDATA[
<p>In a sheep model, we investigated diet effects on skeletal muscle mitochondria to look for fetal programming. During pregnancy, ewes were fed normally (N) or were 50% food restricted (L) during the last trimester, and lambs born to these ewes received a normal (N) or a high-fat diet (H) for the first 6 mo of life. We examined mitochondrial function in permeabilized muscle fibers from the lambs at 6 mo of age (adolescence) and after 24 mo of age (adulthood). The postpartum H diet for the lambs induced an ~30% increase (<I>P</I> &lt; 0.05) of mitochondrial V<scp>o</scp><SUB>2max</SUB> and an ~50% increase (<I>P</I> &lt; 0.05) of the respiratory coupling ratio (RCR) combined with lower levels of UCP3 and PGC-1 mRNA levels (<I>P</I> &lt; 0.05). These effects proved to be reversible by a normal diet from 6 to 24 mo of age. However, at 24 mo, a long-term effect of the maternal gestational diet restriction (fetal programming) became evident as a lower V<scp>o</scp><SUB>2max</SUB> (~40%, <I>P</I> &lt; 0.05), a lower state 4 respiration (~40%, <I>P</I> &lt; 0.05), and lower RCR (~15%, <I>P</I> &lt; 0.05). Both PGC-1 and UCP3 mRNA levels were increased (<I>P</I> &lt; 0.05). Two analyzed muscles were affected differently, and muscle rich in type I fibers was more susceptible to fetal programming. We conclude that fetal programming, seen as a reduced V<scp>o</scp><SUB>2max</SUB> in adulthood, results from gestational undernutrition. Postnatal high-fat diet results in a pronounced RCR and V<scp>o</scp><SUB>2max</SUB> increase in adolescence. However, these effects are reversible by diet correction and are not maintained in adulthood.</p>
]]></description>
<dc:creator><![CDATA[Jorgensen, W., Gam, C., Andersen, J. L., Schjerling, P., Scheibye-Knudsen, M., Mortensen, O. H., Grunnet, N., Nielsen, M. O., Quistorff, B.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00505.2009</dc:identifier>
<dc:title><![CDATA[Changed mitochondrial function by pre- and/or postpartum diet alterations in sheep]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1357</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1349</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1358?rss=1">
<title><![CDATA[Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1358?rss=1</link>
<description><![CDATA[
<p>Glucose ingestion stimulates the secretion of the incretin hormones, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). Despite the critical role of incretins in glucose homeostasis, the mechanism of glucose-induced incretin secretion has not been established. We investigated the underlying mechanism of glucose-induced incretin secretion in vivo in mice. Injection of glucose at 1 g/kg in the upper intestine significantly increased plasma GIP and GLP-1 levels, whereas injection of glucose in the colon did not increase GIP or GLP-1 levels. This finding indicates that the glucose sensor for glucose-induced incretin secretion is in the upper intestine. Coadministration of a sodium-glucose cotransporter-1 (SGLT1) inhibitor, phloridzin, with glucose in the upper intestine blocked glucose absorption and glucose-induced incretin secretion. -methyl-<scp>d</scp>-glucopyranoside (MDG), an SGLT1 substrate that is a nonmetabolizable sugar, significantly increased plasma GIP and GLP-1 levels, whereas phloridzin blocked these increases, indicating that concomitant transport of sodium ions and glucose (substrate) via SGLT1 itself triggers incretin secretion without the need for subsequent glucose metabolism. Interestingly, oral administration of MDG significantly increased plasma GIP, GLP-1, and insulin levels and reduced blood glucose levels during an intraperitoneal glucose tolerance test. Furthermore, chronic MDG treatment in drinking water (3%) for 13 days reduced blood glucose levels after a 2-h fast and in an oral glucose tolerance test in diabetic <I>db/db</I> mice. Our findings indicate that SGLT1 serves as the intestinal glucose sensor for glucose-induced incretin secretion and that a noncalorigenic SGLT1 substrate ameliorates hyperglycemia by stimulating incretin secretion.</p>
]]></description>
<dc:creator><![CDATA[Moriya, R., Shirakura, T., Ito, J., Mashiko, S., Seo, T.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00412.2009</dc:identifier>
<dc:title><![CDATA[Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1365</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1358</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1366?rss=1">
<title><![CDATA[Attenuation of diabetes-induced renal dysfunction by multiple exposures to low-dose radiation is associated with the suppression of systemic and renal inflammation]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1366?rss=1</link>
<description><![CDATA[
<p>Renal protection against diabetes-induced pathogenic injuries by multiple exposures to low-dose radiation (LDR) was investigated to develop a novel approach to the prevention of renal disease for diabetic subjects. C57BL/6J mice were given multiple low-dose streptozotocin (STZ; 60 <FONT FACE="arial,helvetica">x</FONT> 6 mg/kg) to produce a type 1 diabetes. Two weeks after diabetes onset, some of diabetic mice and age-matched nondiabetic mice were exposed whole body to 25 mGy X-rays every other day for 2, 4, 8, 12, and 16 wk. Diabetes caused a significant renal dysfunction, shown by time-dependent increase in urinary microalbumin (Malb) and decrease in urinary creatinine (Cre), and pathological changes, shown by significant increases in renal structural changes and PAS-positive staining. However, diabetes-induced renal dysfunction and pathological changes were significantly, albeit partially, attenuated by multiple exposures to LDR. Furthermore, LDR protection against diabetes-induced renal dysfunction and pathological changes was associated with a significant suppression of diabetes-increased systemic and renal inflammation, shown by significant increases in serum and renal TNF, ICAM-1, IL-18, MCP-1, and PAI-1 contents. To further explore the mechanism by which LDR prevents diabetes-induced renal pathological changes, renal oxidative damage was examined by Western blotting and immunohistochemical staining for 3-nitrotyrosine and 4-hydroxynonenal. Significant increase in oxidative damage was observed in diabetic mice, but not diabetic mice, with LDR. Renal fibrosis, examined by Western blotting of connective tissue growth factor and Masson's trichrome staining, was also evident in the kidneys of diabetic mice but not diabetic mice with LDR. These results suggest that multiple exposures to LDR significantly suppress diabetes-induced systemic and renal inflammatory response and renal oxidative damage, resulting in a prevention of the renal dysfunction and fibrosis.</p>
]]></description>
<dc:creator><![CDATA[Zhang, C., Tan, Y., Guo, W., Li, C., Ji, S., Li, X., Cai, L.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00478.2009</dc:identifier>
<dc:title><![CDATA[Attenuation of diabetes-induced renal dysfunction by multiple exposures to low-dose radiation is associated with the suppression of systemic and renal inflammation]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1377</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1366</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1378?rss=1">
<title><![CDATA[Pigment epithelium-derived factor suppresses adipogenesis via inhibition of the MAPK/ERK pathway in 3T3-L1 preadipocytes]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1378?rss=1</link>
<description><![CDATA[
<p>We previously reported that circulating levels of pigment epithelium-derived factor (PEDF), a newly identified adipokine, are increased in patients with type 2 diabetes, correlating with body mass index. However, the role of PEDF in adipogenesis remains elusive. In the present study, we have investigated the effects and mechanisms of PEDF on adipocyte differentiation in 3T3-L1 preadipocytes. Differentiation of 3T3-L1 preadipocytes was induced in the presence or absence of human recombinant PEDF protein. The effects of PEDF on adipogenic gene expression, mitotic clonal expansion (MCE), and MAPK activation were investigated. Physiological concentrations of human PEDF protein inhibited adipocyte differentiation, evidenced by decreased lipid accumulation, downregulation of adipocyte markers, and inhibition of master adipogenic transcription factors such as C/EBP- and PPAR. The antiadipogenic effects of PEDF were observed only when PEDF was added to the cells on <I>day 0</I>, but not on <I>day 3</I> during differentiation, suggesting that PEDF targets some early adipogenic events. Similarly, overexpression of PEDF by adenovirus attenuated adipocyte differentiation. Further studies revealed that PEDF, or U-0126, a specific MAPK/ERK inhibitor, sequentially inhibited the early activation of ERK and MCE. Moreover, PEDF attenuated expression and the phosphorylation of C/EBP-&beta; at Thr<sup>188</sup>, an essential step for transcriptional activation of C/EBP-&beta;. In addition, PEDF expression was decreased significantly in the first 24 h during adipocyte differentiation, suggesting that downregulation of PEDF may be essential for the initiation of MCE and adipogenesis. We conclude that PEDF inhibits adipogenesis in 3T3-L1 preadipocytes partially because of inhibition of the MAPK/ERK signaling pathway and MCE.</p>
]]></description>
<dc:creator><![CDATA[Wang, M., Wang, J. J., Li, J., Park, K., Qian, X., Ma, J.-x., Zhang, S. X.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00252.2009</dc:identifier>
<dc:title><![CDATA[Pigment epithelium-derived factor suppresses adipogenesis via inhibition of the MAPK/ERK pathway in 3T3-L1 preadipocytes]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1387</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1378</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1388?rss=1">
<title><![CDATA[Role of the AMPK{gamma}3 isoform in hypoxia-stimulated glucose transport in glycolytic skeletal muscle]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1388?rss=1</link>
<description><![CDATA[
<p>Skeletal muscle glucose transport is regulated via the canonical insulin-signaling cascade as well as by energy-sensing signals. 5'-AMP-activated protein kinase (AMPK) has been implicated in the energy status regulation of glucose transport. We determined the role of the AMPK3 isoform in hypoxia-mediated energy status signaling and glucose transport in fast-twitch glycolytic extensor digitorum longus (EDL) muscle from AMPK3-knockout (KO) mice and wild-type mice. Although hypoxia increased glucose transport (<I>P</I> &lt; 0.001) in wild-type mice, this effect was attenuated in AMPK3-KO mice (45% reduction, <I>P</I> &lt; 0.01). The role of Ca<sup>2+</sup>-mediated signaling was tested using the Ca<sup>2+</sup>/calmodulin competitive inhibitor KN-93. KN-93 exposure reduced hypoxia-mediated glucose transport in AMPK3-KO and wild-type mice (<I>P</I> &lt; 0.05). To further explore the underlying signaling mechanisms, phosphorylation of CaMKII, AMPK, ACC, and TBC1D1/D4 as well as isoform-specific AMPK activity was determined. Basal and hypoxia-mediated phosphorylation of CaMKII, AMPK, and ACC as well as 1- and 2-associated AMPK activity was comparable between AMPK3-KO and wild-type mice. KN-93 reduced hypoxia-mediated CaMKII phosphorylation in AMPK3-KO and wild-type mice (<I>P</I> &lt; 0.05), whereas phosphorylation of AMPK and ACC as well as 1- and 2-associated AMPK activity was unaltered. Hypoxia increased TBC1D1/D4 phosphorylation in AMPK3-KO and wild-type mice (<I>P</I> &lt; 0.001). KN-93 exposure prevented this effect in AMPK3-KO, but not in wild-type mice. Taken together, we provide direct evidence for a role of the AMPK3 isoform in hypoxia-mediated glucose transport in glycolytic muscle. Moreover, hypoxia-mediated TBC1D1/D4 phosphorylation was uncoupled from glucose transport in AMPK3-KO mice, indicating that TBC1D1/D4-independent mechanisms contribute to glucose transport in skeletal muscle.</p>
]]></description>
<dc:creator><![CDATA[Deshmukh, A. S., Glund, S., Tom, R. Z., Zierath, J. R.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00125.2009</dc:identifier>
<dc:title><![CDATA[Role of the AMPK{gamma}3 isoform in hypoxia-stimulated glucose transport in glycolytic skeletal muscle]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1394</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1388</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1395?rss=1">
<title><![CDATA[Functional analysis of FSP27 protein regions for lipid droplet localization, caspase-dependent apoptosis, and dimerization with CIDEA]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1395?rss=1</link>
<description><![CDATA[
<p>The adipocyte-specific protein FSP27, also known as CIDEC, is one of three cell death-inducing DFF45-like effector (CIDE) proteins. The first known function for CIDEs was promotion of apoptosis upon ectopic expression in mammalian cells. Recent studies in endogenous settings demonstrated key roles for CIDEs in energy metabolism. FSP27 is a lipid droplet-associated protein whose heterologous expression enhances formation of enlarged lipid droplets and is required for unilocular lipid droplets typical of white adipocytes in vivo. Here, we delineate relationships between apoptotic function and lipid droplet localization of FSP27. We demonstrate that ectopic expression of FSP27 induces enlarged lipid droplets in multiple human cell lines, which is indicative that its mechanism involves ubiquitously present, rather than adipocyte-specific, cellular machinery. Furthermore, promotion of lipid droplet formation in HeLa cells via culture in exogenous oleic acid offsets FSP27-mediated apoptosis. Using transient cotransfections and analysis of lipid droplets in HeLa cells stably expressing FSP27, we show that FSP27 does not protect lipid droplets from action of ATGL lipase. Domain mapping with eGFP-FSP27 deletion constructs indicates that lipid droplet localization of FSP27 requires amino acids 174&ndash;192 of its CIDE C domain. The apoptotic mechanism of FSP27, which we show involves caspase-9 and mitochondrial cytochrome <I>c</I>, also requires this 19-amino acid region. Interaction assays determine the FSP27 CIDE C domain complexes with CIDEA, and Western blot reveals that FSP27 protein levels are reduced by coexpression of CIDEA. Overall, our findings demonstrate the function of the FSP27 CIDE C domain and/or regions thereof for apoptosis, lipid droplet localization, and CIDEA interaction.</p>
]]></description>
<dc:creator><![CDATA[Liu, K., Zhou, S., Kim, J.-Y., Tillison, K., Majors, D., Rearick, D., Lee, J. H., Fernandez-Boyanapalli, R. F., Barricklow, K., Houston, M. S., Smas, C. M.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00188.2009</dc:identifier>
<dc:title><![CDATA[Functional analysis of FSP27 protein regions for lipid droplet localization, caspase-dependent apoptosis, and dimerization with CIDEA]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1413</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1395</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1414?rss=1">
<title><![CDATA[Lactate distribution in culture medium of human myometrial biopsies incubated under different conditions]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1414?rss=1</link>
<description><![CDATA[
<p>It is generally believed that a relationship exists between muscle fatigue and intracellular accumulation of lactate. This reasoning is relevant to obstetrical issues. Myocytes in uterus work together during labor, and the contractions need to be strong and synchronized for a child to be delivered. At labor dystocia, the progress of labor becomes slow or arrested after a normal beginning. It has been described that, during labor dystocia, when the force of the contractions is low, the uterus is under hypoxia, and anaerobic conditions with high levels of lactate in amniotic fluid dominate. The purpose of this study was to examine whether myometrial cells are involved in the production of lactate in amniotic fluid and whether there are differences in production and distribution of lactate in cells incubated under aerobic and anaerobic conditions. We also wanted to elucidate the involvement of specific membrane-bound lactate carriers. Women undergoing elective caesarean section were included. Myometrial biopsies from uteri were collected and subjected to either immunohistochemistry to identify lactate carriers or in vitro experiments to analyze production of lactate. The presence of lactate carriers named monocarboxylate transporters 1 and 4 was verified. Myometrial cells produced lactate extracellularly, and the lactate carriers operated differently under anaerobic and aerobic conditions; while being mainly unidirectional under anaerobic conditions, they became bidirectional under aerobic conditions. Human myometrial cells produced and delivered lactate to the extracellular medium under both anaerobic and aerobic conditions. The delivery was mediated by lactate carriers.</p>
]]></description>
<dc:creator><![CDATA[Akerud, H., Ronquist, G., Wiberg-Itzel, E.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00458.2009</dc:identifier>
<dc:title><![CDATA[Lactate distribution in culture medium of human myometrial biopsies incubated under different conditions]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1419</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1414</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1420?rss=1">
<title><![CDATA[Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/6/E1420?rss=1</link>
<description><![CDATA[
<p>The synthetic retinoid Fenretinide (FEN) increases insulin sensitivity in obese rodents and is in early clinical trials for treatment of insulin resistance in obese humans with hepatic steatosis (46). We aimed to determine the physiological mechanisms for the insulin-sensitizing effects of FEN. Wild-type mice were fed a high-fat diet (HFD) with or without FEN from 4&ndash;5 wk to 36&ndash;37 wk of age (preventive study) or following 22 wk of HF diet-induced obesity (12 wk intervention study). Retinol-binding protein-4 (RBP4) knockout mice were also fed the HFD with or without FEN in a preventive study. FEN had minimal effects on HFD-induced body weight gain but markedly reduced HFD-induced adiposity and hyperleptinemia in both studies. FEN-HFD mice gained epididymal fat but not subcutaneous or visceral fat mass in contrast to HFD mice without FEN. FEN did not have a measurable effect on energy expenditure, food intake, physical activity, or stool lipid content. Glucose infusion rate during hyperinsulinemic-euglycemic clamp was reduced 86% in HFD mice compared with controls and was improved 3.6-fold in FEN-HFD compared with HFD mice. FEN improved insulin action on glucose uptake and glycogen levels in muscle, insulin-stimulated suppression of hepatic glucose production, and suppression of serum FFA levels in HFD mice. Remarkably, FEN also reduced hepatic steatosis. In RBP4 knockout mice, FEN reduced the HFD-induced increase in adiposity and hyperleptinemia. In conclusion, long-term therapy with FEN partially prevents or reverses obesity, insulin resistance, and hepatic steatosis in mice on HFD. The anti-adiposity effects are independent of the RBP4 lowering effect.</p>
]]></description>
<dc:creator><![CDATA[Preitner, F., Mody, N., Graham, T. E., Peroni, O. D., Kahn, B. B.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:29:18 PST</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00362.2009</dc:identifier>
<dc:title><![CDATA[Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>6</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1429</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>E1420</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/full/297/5/E975?rss=1">
<title><![CDATA[Adipose tissue function and dysfunction: organ cross talk and metabolic risk]]></title>
<link>http://ajpendo.physiology.org/cgi/content/full/297/5/E975?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Giorgino, F.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00488.2009</dc:identifier>
<dc:title><![CDATA[Adipose tissue function and dysfunction: organ cross talk and metabolic risk]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E976</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E975</prism:startingPage>
<prism:section>Editorial Focus</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E977?rss=1">
<title><![CDATA[Transdifferentiation properties of adipocytes in the adipose organ]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E977?rss=1</link>
<description><![CDATA[
<p>Mammals have two types of adipocytes, white and brown, but their anatomy and physiology is different. White adipocytes store lipids, and brown adipocytes burn them to produce heat. Previous descriptions implied their localization in distinct sites, but we demonstrated that they are mixed in many depots, raising the concept of adipose organ. We explain the reason for their cohabitation with the hypothesis of reversible physiological transdifferentiation; they are able to convert one into each other. If needed, the brown component of the organ could increase at the expense of the white component and vice versa. This plasticity is important because the brown phenotype of the organ associates with resistance to obesity and related disorders. Another example of physiological transdifferetiation of adipocytes is offered by the mammary gland; the pregnancy hormonal stimuli seems to trigger a reversible transdifferentiation of adipocytes into milk-secreting epithelial glands. The obese adipose organ is infiltrated by macrophages inducing chronic inflamation that is widely considered as a causative factor for insulin resistance. We showed that the vast majority of macrophages infiltrating the obese organ are arranged around dead adipocytes, forming characteristic crown-like structures. We recently found that visceral fat is more infiltrated than the subcutaneous fat despite a smaller size of visceral adipocytes. This suggests a different susceptibility of visceral and subcutaneous adipocytes to death, raising the concept of smaller critical death size that could be important to explain the key role of visceral fat for the metabolic disorders associated with obesity.</p>
]]></description>
<dc:creator><![CDATA[Cinti, S.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00183.2009</dc:identifier>
<dc:title><![CDATA[Transdifferentiation properties of adipocytes in the adipose organ]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E986</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E977</prism:startingPage>
<prism:section>Reviews</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E987?rss=1">
<title><![CDATA[The origin of intermuscular adipose tissue and its pathophysiological implications]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E987?rss=1</link>
<description><![CDATA[
<p>The intermuscular adipose tissue (IMAT) is a depot of adipocytes located between muscle bundles. Several investigations have recently been carried out to define the phenotype, the functional characteristics, and the origin of the adipocytes present in this depot. Among the different mechanisms that could be responsible for the accumulation of fat in this site, the dysdifferentiation of muscle-derived stem cells or other mesenchymal progenitors has been postulated, turning them into cells with an adipocyte phenotype. In particular, muscle satellite cells (SCs), a heterogeneous stem cell population characterized by plasticity and self-renewal that allow muscular growth and regeneration, can acquire features of adipocytes, including the abilities to express adipocyte-specific genes and accumulate lipids. Failure to express the transcription factors that direct mesenchymal precursors into fully differentiated functionally specialized cells may be responsible for their phenotypic switch into the adipogenic lineage. We proved that human SCs also possess a clear adipogenic potential that could explain the presence of mature adipocytes within skeletal muscle. This occurs under some pathological conditions (i.e., primary myodystrophies, obesity, hyperglycemia, high plasma free fatty acids, hypoxia, etc.) or as a consequence of thiazolidinedione treatment or simply because of a sedentary lifestyle or during aging. Several pathways and factors (PPARs, WNT growth factors, myokines, GEF-GAP-Rho, p66<sup>shc</sup>, mitochondrial ROS production, PKC&beta;) could be implicated in the adipogenic conversion of SCs. The understanding of the molecular pathways that regulate muscle-to-fat conversion and SC behavior could explain the increase in IMAT depots that characterize many metabolic diseases and age-related sarcopenia.</p>
]]></description>
<dc:creator><![CDATA[Vettor, R., Milan, G., Franzin, C., Sanna, M., De Coppi, P., Rizzuto, R., Federspil, G.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00229.2009</dc:identifier>
<dc:title><![CDATA[The origin of intermuscular adipose tissue and its pathophysiological implications]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E998</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E987</prism:startingPage>
<prism:section>Reviews</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E999?rss=1">
<title><![CDATA[Inflammation and impaired adipogenesis in hypertrophic obesity in man]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E999?rss=1</link>
<description><![CDATA[
<p>Obesity is associated mainly with adipose cell enlargement in adult man (hypertrophic obesity), whereas the formation of new fat cells (hyperplastic obesity) predominates in the prepubertal age. Adipose cell size, independent of body mass index, is negatively correlated with whole body insulin sensitivity. Here, we review recent findings linking hypertrophic obesity with inflammation and a dysregulated adipose tissue, including local cellular insulin resistance with reduced IRS-1 and GLUT4 protein content. In addition, the number of preadipocytes in the abdominal subcutaneous adipose tissue capable of undergoing differentiation to adipose cells is reduced in hypertrophic obesity. This is likely to promote ectopic lipid accumulation, a well-known finding in these individuals and one that promotes insulin resistance and cardiometabolic risk. We also review recent results showing that TNF, but not MCP-1, resistin, or IL-6, completely prevents normal adipogenesis in preadipocytes, activates Wnt signaling, and induces a macrophage-like phenotype in the preadipocytes. In fact, activated preadipocytes, rather than macrophages, may completely account for the increased release of chemokines and cytokines by the adipose tissue in obesity. Understanding the molecular mechanisms for the impaired preadipocyte differentiation in the subcutaneous adipose tissue in hypertrophic obesity is a priority since it may lead to new ways of treating obesity and its associated metabolic complications.</p>
]]></description>
<dc:creator><![CDATA[Gustafson, B., Gogg, S., Hedjazifar, S., Jenndahl, L., Hammarstedt, A., Smith, U.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00377.2009</dc:identifier>
<dc:title><![CDATA[Inflammation and impaired adipogenesis in hypertrophic obesity in man]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1003</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E999</prism:startingPage>
<prism:section>Reviews</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1004?rss=1">
<title><![CDATA[Role of lipid-derived mediators in skeletal muscle insulin resistance]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1004?rss=1</link>
<description><![CDATA[
<p>Imbalance between nutritional intake and energy expenditure has been described to culminate in obesity, which predisposes to insulin resistance and type 2 diabetes mellitus. In such states of energy oversupply, excess amounts of lipids are available in tissues and circulation. Over the past years, an increasingly important role in development of skeletal muscle (SkM) insulin resistance has been attributed to lipids and impaired fatty acid metabolism. In this review, we reflect the current state of knowledge about the effects of various lipid-derived mediators on SkM insulin sensitivity. Furthermore, potential mechanisms underlying the biogenesis of intramyocellular ectopic lipid stores are discussed. Previously, a pivotal role was attributed to mitochondrial dysfunction. However, results of recent studies have suggested an important role for exercise deficiency, accompanied by decreased expression levels of peroxisome proliferator-activated receptor- coactivator-1 and subsequent, incomplete &beta;-oxidation. Additionally, we summarize the implications of increased levels of lipid-derived endocannabinoids (ECs) for metabolic control in peripheral tissue and highlight the benefits of targeting the EC system.</p>
]]></description>
<dc:creator><![CDATA[Taube, A., Eckardt, K., Eckel, J.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00241.2009</dc:identifier>
<dc:title><![CDATA[Role of lipid-derived mediators in skeletal muscle insulin resistance]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1012</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1004</prism:startingPage>
<prism:section>Reviews</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1013?rss=1">
<title><![CDATA[Critical roles for the TSC-mTOR pathway in {beta}-cell function]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1013?rss=1</link>
<description><![CDATA[
<p>TSC1 is a tumor suppressor that associates with TSC2 to inactivate Rheb, thereby inhibiting signaling by the mammalian target of rapamycin (mTOR) complex 1 (mTORC1). mTORC1 stimulates cell growth by promoting anabolic cellular processes, such as translation, in response to growth factors and nutrient signals. To test roles for TSC1 and mTORC1 in &beta;-cell function, we utilized <I>Rip2</I>/<I>Cre</I> to generate mice lacking <I>Tsc1</I> in pancreatic &beta;-cells (<I>Rip-Tsc1</I>cKO mice). Although obesity developed due to hypothalamic <I>Tsc1</I> excision in older <I>Rip-Tsc1</I>cKO animals, young animals displayed a prominent gain-of-function &beta;-cell phenotype prior to the onset of obesity. The young <I>Rip-Tsc1</I>cKO animals displayed improved glycemic control due to mTOR-mediated enhancement of &beta;-cell size, mass, and insulin production but not determinants of &beta;-cell number (proliferation and apoptosis), consistent with an important anabolic role for mTOR in &beta;-cell function. Furthermore, mTOR mediated these effects in the face of impaired Akt signaling in &beta;-cells. Thus, mTOR promulgates a dominant signal to promote &beta;-cell/islet size and insulin production, and this pathway is crucial for &beta;-cell function and glycemic control.</p>
]]></description>
<dc:creator><![CDATA[Mori, H., Inoki, K., Opland, D., Munzberg, H., Villanueva, E. C., Faouzi, M., Ikenoue, T., Kwiatkowski, D. J., MacDougald, O. A., Myers, M. G., Guan, K.-L.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00262.2009</dc:identifier>
<dc:title><![CDATA[Critical roles for the TSC-mTOR pathway in {beta}-cell function]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1022</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1013</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1023?rss=1">
<title><![CDATA[Comparison between surrogate indexes of insulin sensitivity/resistance and hyperinsulinemic euglycemic clamp estimates in rats]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1023?rss=1</link>
<description><![CDATA[
<p>Assessing insulin resistance in rodent models gives insight into mechanisms that cause type 2 diabetes and the metabolic syndrome. The hyperinsulinemic euglycemic glucose clamp, the reference standard for measuring insulin sensitivity in humans and animals, is labor intensive and technically demanding. A number of simple surrogate indexes of insulin sensitivity/resistance have been developed and validated primarily for use in large human studies. These same surrogates are also frequently used in rodent studies. However, in general, these indexes have not been rigorously evaluated in animals. In a recent validation study in mice, we demonstrated that surrogates have a weaker correlation with glucose clamp estimates of insulin sensitivity/resistance than in humans. This may be due to increased technical difficulties in mice and/or intrinsic differences between human and rodent physiology. To help distinguish among these possibilities, in the present study, using data from rats substantially larger than mice, we compared the clamp glucose infusion rate (GIR) with surrogate indexes, including QUICKI, HOMA, 1/HOMA, log (HOMA), and 1/fasting insulin. All surrogates were modestly correlated with GIR (<I>r</I> = 0.34&ndash;0.40). Calibration analyses of surrogates adjusted for body weight demonstrated similar predictive accuracy for GIR among all surrogates. We conclude that linear correlations of surrogate indexes with clamp estimates and predictive accuracy of surrogate indexes in rats are similar to those in mice (but not as substantial as in humans). This additional rat study (taken with the previous mouse study) suggests that application of surrogate insulin sensitivity indexes developed for humans may not be appropriate for determining primary outcomes in rodent studies due to intrinsic differences in metabolic physiology. However, use of surrogates may be appropriate in rodents, where feasibility of clamps is an obstacle and measurement of insulin sensitivity is a secondary outcome.</p>
]]></description>
<dc:creator><![CDATA[Muniyappa, R., Chen, H., Muzumdar, R. H., Einstein, F. H., Yan, X., Yue, L. Q., Barzilai, N., Quon, M. J.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00397.2009</dc:identifier>
<dc:title><![CDATA[Comparison between surrogate indexes of insulin sensitivity/resistance and hyperinsulinemic euglycemic clamp estimates in rats]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1029</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1023</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1030?rss=1">
<title><![CDATA[Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1030?rss=1</link>
<description><![CDATA[
<p>The present study attempted to define the role of hepatic Niemann-Pick C1-like 1 (NPC1L1), a cholesterol transporter, in hepatic insulin resistance as well as hepatic steatosis. The inhibition of NPC1L1 and its molecular consequences were examined in Zucker obese fatty (ZOF) rats and cultured steatotic hepatocytes using ezetimibe, a pharmacoloigcal inhibitor of NPC1L1, and short hairpin RNA (shRNA) of NPC1L1. Ezetimibe improved hepatic insulin signaling as well as hepatic steatosis in ZOF rats. It also restored insulin sensitivity in steatotic hepatocytes in vitro through a reduction in hepatic reactive oxygen species (ROS) generation, JNK activation, and ER stress. In addition, ezetimibe recovered insulin-induced Akt activation and reduced gluconeogenic genes in the liver of ZOF rats and cultured steatotic hepatocytes. Transfection of NPC1L1 shRNA into hepatocytes also reduced ROS generation and ER stress. These results indicate that NPC1L1 contributes to hepatic insulin resistance through cholesterol accumulation, and its inhibition could be a potential therapeutic target of hepatic insulin resistance.</p>
]]></description>
<dc:creator><![CDATA[Nomura, M., Ishii, H., Kawakami, A., Yoshida, M.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00343.2009</dc:identifier>
<dc:title><![CDATA[Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1038</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1030</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1039?rss=1">
<title><![CDATA[Effects of hypoxia on testosterone release in rat Leydig cells]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1039?rss=1</link>
<description><![CDATA[
<p>The aim of this study was to explore the effect and action mechanisms of intermittent hypoxia on the production of testosterone both in vivo and in vitro. Male rats were housed in a hypoxic chamber (12% O<SUB>2</SUB> + 88% N<SUB>2</SUB>, 1.5 l/ml) 8 h/day for 4 days. Normoxic rats were used as control. In an in vivo experiment, hypoxic and normoxic rats were euthanized and the blood samples collected. In the in vitro experiment, the enzymatically dispersed rat Leydig cells were prepared and challenged with forskolin (an adenylyl cyclase activator, 10<sup>&ndash;4</sup> M), 8-Br-cAMP (a membrane-permeable analog of cAMP, 10<sup>&ndash;4</sup> M), hCG (0.05 IU), the precursors of the biosynthesis testosterone, including 25-OH-C (10<sup>&ndash;5</sup> M), pregnenolone (10<sup>&ndash;7</sup> M), progesterone (10<sup>&ndash;7</sup> M), 17-OH-progesterone (10<sup>&ndash;7</sup> M), and androstendione (10<sup>&ndash;7</sup>-10<sup>&ndash;5</sup> M), nifedipine (L-type Ca<sup>2+</sup> channel blocker, 10<sup>&ndash;6</sup>-10<sup>&ndash;4</sup> M), nimodipine (L-type Ca<sup>2+</sup> channel blocker, 10<sup>&ndash;5</sup> M), tetrandrine (L-type Ca<sup>2+</sup> channel blocker, 10<sup>&ndash;5</sup> M), and NAADP (calcium-signaling messenger causing release of calcium from intracellular stores, 10<sup>&ndash;6</sup>-10<sup>&ndash;4</sup> M). The concentrations of testosterone in plasma and medium were measured by radioimmunoassay. The level of plasma testosterone in hypoxic rats was higher than that in normoxic rats. Enhanced testosterone production was observed in rat Leydig cells treated with hCG, 8-Br-cAMP, or forskolin in both normoxic and hypoxic conditions. Intermittent hypoxia resulted in a further increase of testosterone production in response to the testosterone precursors. The activity of 17&beta;-hydroxysteroid dehydrogenase was stimulated by the treatment of intermittent hypoxia in vitro. The intermittent hypoxia-induced higher production of testosterone was accompanied with the influx of calcium via L-type calcium channel and the increase of intracellular calcium via the mechanism of calcium mobilization. These results suggested that the intermittent hypoxia stimulated the secretion of testosterone at least in part via stimulatory actions on the activities of adenylyl cyclase, cAMP, L-type calcium channel, and steroidogenic enzymes.</p>
]]></description>
<dc:creator><![CDATA[Hwang, G.-S., Chen, S.-T., Chen, T.-J., Wang, S.-W.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00010.2009</dc:identifier>
<dc:title><![CDATA[Effects of hypoxia on testosterone release in rat Leydig cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1045</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1039</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1046?rss=1">
<title><![CDATA[Ontogeny of methionine utilization and splanchnic uptake in critically ill children]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1046?rss=1</link>
<description><![CDATA[
<p>To determine the rates of methionine splanchnic uptake and utilization in critically ill pediatric patients we used two kinetic models: the plasma methionine enrichment and the "intracellular" homocysteine enrichment. Twenty four patients, eight infants, eight children, and eight adolescents, were studied. They received simultaneous, primed, constant, intravenous infusions of <scp>l</scp>-[<sup>2</sup>H<SUB>3</SUB>]methylmethionine and enteral <scp>l</scp>-[1-<sup>13</sup>C]methionine. The ratio of [<sup>13</sup>C]homocysteine to [<sup>13</sup>C]methionine enrichment was 1.0 &plusmn; 0.15, 0.80 &plusmn; 0.20, and 0.66 &plusmn; 0.10, respectively, for the infants, children, and adolescents, and it was different between the infants and adolescents (<I>P</I> &lt; 0.01). Methionine splanchnic uptake was 63, 45, and 36%, respectively, in the infants, children, and adolescents, and it was higher (<I>P</I> &lt; 0.01) in the infants compared with the adolescents. The infants utilized 73% of methionine flux for nonoxidative disposal, while 27% was used for transulfuration (<I>P</I> &lt; 0.001). Conversely, in the adolescents, 40% was utilized for nonoxidative disposal, while 60% was used for transulfuration. There is ontogeny on the rates of methionine splanchnic uptake and on the fate of methionine utilization in critically ill children, with greater methionine utilization for synthesis of proteins and methionine-derived compounds (<I>P</I> &lt; 0.01) and decreased transulfuration rates in the infants (<I>P</I> &lt; 0.01), while the opposite was observed in the adolescents. The plasma model underestimated methionine kinetics in children and adolescents but not in the infants, suggesting lesser dilution and greater compartmentation of methionine metabolism in the infant population. All patients were in negative methionine balance, indicating that the current enteral nutritional support is inadequate in these patients.</p>
]]></description>
<dc:creator><![CDATA[Verbruggen, S., Sy, J., Gordon, W. E., Hsu, J., Wu, M., Chacko, S., Zurakowski, D., Burrin, D., Castillo, L.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00396.2009</dc:identifier>
<dc:title><![CDATA[Ontogeny of methionine utilization and splanchnic uptake in critically ill children]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1055</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1046</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1056?rss=1">
<title><![CDATA[Restoring AS160 phosphorylation rescues skeletal muscle insulin resistance and fatty acid oxidation while not reducing intramuscular lipids]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1056?rss=1</link>
<description><![CDATA[
<p>We examined whether AICAR or leptin rapidly rescued skeletal muscle insulin resistance via increased palmitate oxidation, reductions in intramuscular lipids, and/or restoration of insulin-stimulated AS60 phosphorylation. Incubation with palmitate (2 mM, 0&ndash;18 h) induced insulin resistance in soleus muscle. From 12&ndash;18 h, palmitate was removed or AICAR or leptin was provided while 2 mM palmitate was maintained. Palmitate oxidation, intramuscular triacylglycerol, diacylglycerol, ceramide, AMPK phosphorylation, basal and insulin-stimulated glucose transport, plasmalemmal GLUT4, and Akt and AS160 phosphorylation were examined at 0, 6, 12, and 18 h. Palmitate treatment (12 h) increased intramuscular lipids (triacylglycerol +54%, diacylglycerol +11%, total ceramide +18%, C16:0 ceramide +60%) and AMPK phosphorylation (+118%), whereas it reduced fatty acid oxidation (&ndash;60%) and insulin-stimulated glucose transport (&ndash;70%), GLUT4 translocation (&ndash;50%), and AS160 phosphorylation (&ndash;40%). Palmitate removal did not rescue insulin resistance or associated parameters. The AICAR and leptin treatments did not consistently reduce intramuscular lipids, but they did rescue palmitate oxidation and insulin-stimulated glucose transport, GLUT4 translocation, and AS160 phosphorylation. Increased AMPK phosphorylation was associated with these improvements only when AICAR and leptin were present. Hence, across all experiments, AMPK phosphorylation did not correlate with any parameters. In contrast, palmitate oxidation and insulin-stimulated AS160 phosphorylation were highly correlated (<I>r</I> = 0.83). We speculate that AICAR and leptin activate both of these processes concomitantly, involving activation of unknown kinases in addition to AMPK. In conclusion, despite the maintenance of high concentrations of palmitate (2 mM), as well as increased concentrations of intramuscular lipids (triacylglycerol, diacylglycerol, and ceramide), the rapid AICAR- and leptin-mediated rescue of palmitate-induced insulin resistance is attributable to the restoration of insulin-stimulated AS160 phosphorylation and GLUT4 translocation.</p>
]]></description>
<dc:creator><![CDATA[Alkhateeb, H., Chabowski, A., Glatz, J. F. C., Gurd, B., Luiken, J. J. F. P., Bonen, A.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90908.2008</dc:identifier>
<dc:title><![CDATA[Restoring AS160 phosphorylation rescues skeletal muscle insulin resistance and fatty acid oxidation while not reducing intramuscular lipids]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1066</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1056</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1067?rss=1">
<title><![CDATA[Overexpression of the nuclear factor-{kappa}B subunit c-Rel protects against human islet cell death in vitro]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1067?rss=1</link>
<description><![CDATA[
<p>The transcription factor nuclear factor (NF)-B is known to modulate rates of apoptosis and may therefore play a role in the increased &beta;-cell death that occurs in type 1 and type 2 diabetes. The aim of the present investigation was to study the expression of NF-B subunits in human islet cells and whether overexpression of the NF-B subunit c-Rel affects islet cell survival. We detected expression of p65, Rel-B, p50, p105, p52, and the ribosomal protein S3 (rpS3) in human islet cells. Among these, only p65 and rpS3 were translocated from the cytosolic to the nuclear fraction in response to cytokines. Interestingly, rpS3 participated in p65 binding to the B-element in gel shift analysis experiments. We observed cytoplasmic c-Rel expression in vivo in 6J mice, and signs of nuclear translocation in &beta;-cells of infiltrated nonobese diabetic islets. Human islet cells were also dispersed by trypsin treatment and transduced with a c-Rel adenoviral vector. This resulted in increased expression of c-Rel and inhibitory factor B, increased B-binding activity, and augmented protein levels of Bcl-X<SUB>L,</SUB> c-IAP2, and heat shock protein 72. c-Rel expression in human islet cells protected against cytokine-induced caspase 3 activation and cell death. c-Rel protected also against streptozotocin- and H<SUB>2</SUB>O<SUB>2</SUB>-induced cell death, in both intact rat islets and human islet cells. We conclude that rpS3 participates in NF-B signaling and that a genetic increase in the activity of the NF-B subunit c-Rel results in protection against cell death in human islets.</p>
]]></description>
<dc:creator><![CDATA[Mokhtari, D., Barbu, A., Mehmeti, I., Vercamer, C., Welsh, N.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00212.2009</dc:identifier>
<dc:title><![CDATA[Overexpression of the nuclear factor-{kappa}B subunit c-Rel protects against human islet cell death in vitro]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1077</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1067</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1078?rss=1">
<title><![CDATA[Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1078?rss=1</link>
<description><![CDATA[
<p>Somatostatin receptors (SSTR1&ndash;5) mediate antiproliferative effects. In C6 rat glioma cells, somatostatin is cytostatic in vitro via phosphotyrosine phosphatase-dependent inhibition of ERK1/2 activity mediated by SSTR1, -2, and -5. Here we analyzed the effects of SSTR activation on C6 glioma growth in vivo and the intracellular mechanisms involved, comparing somatostatin effects with selective agonists for SSTR1, -2, and -5 (BIM-23745, BIM-23120, BIM-23206) or receptor biselective compounds (SSTR1 and -2, BIM-23704; and SSTR2 and -5, BIM-23190). Nude mice subcutaneously xenografted with C6 cells were treated with somatostatin, SSTR agonists (50 &micro;g, twice/day), or vehicle. Tumor growth was evaluated every 3 days for 19 days. The intracellular pathways responsible of SSTR effects in vivo were evaluated measuring Ki-67, phospho-ERK1/2, and p27<sup>kip1</sup> expression by immunohistochemistry in sections from explanted tumors. Somatostatin and SSTR1, -2, and -5 agonists strongly inhibited in vivo C6 tumor growth, intratumoral neovessel formation, Ki-67 expression, and ERK1/2 phosphorylation and induced upregulation of p27<sup>Kip1</sup>, whereas only a modest activation of caspase-3 was observed. Somatostatin (acting on SSTR1, -2, and -5) displayed the highest efficacy; SSTR5 selective agonist showed a stronger effect than SSTR1 agonist, and SSTR2 agonist was less effective. On the other hand, SSTR1 and -2 agonists maximally reduced tumor neovascularization. The combined activation of SSTR1 and -2 showed a synergistic activity, reaching a higher efficacy than BIM-23206, whereas the simultaneous activation of SSTR2 and -5 resulted in a response resembling SSTR5 effects. Thus the simultaneous activation of different SSTRs inhibits glioma cell proliferation in vivo through both direct cytotostatic and antiangiogenic effects.</p>
]]></description>
<dc:creator><![CDATA[Barbieri, F., Pattarozzi, A., Gatti, M., Aiello, C., Quintero, A., Lunardi, G., Bajetto, A., Ferrari, A., Culler, M. D., Florio, T.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00292.2009</dc:identifier>
<dc:title><![CDATA[Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1088</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1078</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1089?rss=1">
<title><![CDATA[Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1089?rss=1</link>
<description><![CDATA[
<p>The effects of progesterone on breast epithelial cells remain poorly defined with observations showing both proliferative and antiproliferative effects. As an example, progesterone levels correlate with increased epithelial cell proliferation, but there is discordance between the dividing cells and the cells with nuclear progesterone receptor expression. The release of paracrine growth factors from nuclear receptor-positive cells has been postulated as a mechanism, since in vitro studies show a lack of growth effect by progesterone in breast epithelial cells lacking nuclear receptors. This study examined possible nongenomic effects of progesterone in breast epithelia by using MCF-10A cells known to lack nuclear progesterone receptor expression. Treatment for 30&ndash;60 min with progesterone or the progestin, R5020, increased mitochondrial activity as shown by an increase in mitochondrial membrane potential (hyperpolarization) with a concordant increase in total cellular ATP. The reaction was inhibited by a specific progesterone receptor antagonist and not affected by the translation inhibitor cycloheximide. Progestin treatment inhibited apoptosis induced by activation of the FasL pathway, as shown by a decrease in sub-G<SUB>1</SUB> cell fraction during fluorescence-activated cell sorting and a decrease in caspase 3/7 levels. Progestin treatment did not alter the cell cycle over 48 h. Our study demonstrates a nongenomic action of progesterone on benign breast epithelial cells, resulting in enhanced cellular respiration and protection from apoptosis.</p>
]]></description>
<dc:creator><![CDATA[Behera, M. A., Dai, Q., Garde, R., Saner, C., Jungheim, E., Price, T. M.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00209.2009</dc:identifier>
<dc:title><![CDATA[Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1096</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1089</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1097?rss=1">
<title><![CDATA[A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1097?rss=1</link>
<description><![CDATA[
<p>HIV-infected patients on antiretroviral therapy frequently develop changes in body fat distribution and disturbances in glucose metabolism, associated with reduced adiponectin levels. Because adiponectin, principally the high-molecular-weight (HMW) form, has insulin-sensitizing properties, we investigated the effects of an increase in adiponectin on glucose metabolism in HIV-lipodystrophy. In this randomized, double-blind, placebo-controlled trial, we included HIV-1-infected patients with severe lipoatrophy, with an undetectable viral load and who had received neither protease inhibitors nor stavudine for &ge;6 mo. Patients were randomized to rosiglitazone [8 mg daily (<I>n</I> = 8)] to increase adiponectin levels or placebo (<I>n</I> = 5) for 16 wk. Peripheral glucose disposal, glucose production, and lipolysis were measured after an overnight fast and during a hyperinsulinemic-euglycemic clamp using stable isotopes. Body composition was assessed by computed tomography and dual-energy X-ray absorptiometry. Although body fat distribution was unaffected, rosiglitazone increased total plasma adiponectin levels by 107% (<I>P</I> &lt; 0.02) and the ratio of HMW to total adiponectin by 73% (<I>P</I> &lt; 0.001). In the placebo group, neither total adiponectin levels (<I>P</I> = 0.62) nor the ratio of HMW to total adiponectin changed (<I>P</I> = 0.94). The marked increase in adiponectin induced by rosiglitazone was not associated with significant changes in basal endogenous glucose production (<I>P</I> = 0.90), basal lipolysis (<I>P</I> = 0.90), insulin-mediated suppression of glucose production (<I>P</I> = 0.17) and lipolysis (<I>P</I> = 0.54) nor with changes in peripheral glucose disposal (<I>P</I> = 0.13). Acknowledging the limited statistical power of our small study, these findings, if confirmed by larger studies, could question the importance of adiponectin in regulating glucose metabolism in HIV-lipodystrophy.</p>
]]></description>
<dc:creator><![CDATA[Blumer, R. M. E., van der Valk, M., Ackermans, M., Endert, E., Serlie, M. J., Reiss, P., Sauerwein, H. P.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90988.2008</dc:identifier>
<dc:title><![CDATA[A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1104</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1097</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1105?rss=1">
<title><![CDATA[Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1105?rss=1</link>
<description><![CDATA[
<p> Recombinant fibroblast growth factor (FGF)21 has antihyperglycemic, antihyperlipidemic, and antiobesity effects in diabetic rodent and monkey models. Previous studies were confined to measuring steady-state effects of FGF21 following subchronic or chronic administration. The present study focuses on the kinetics of biological actions of FGF21 following a single injection and on the associated physiological and cellular mechanisms underlying FGF21 actions. We show that FGF21 resulted in rapid decline of blood glucose levels and immediate improvement of glucose tolerance and insulin sensitivity in two animal models of insulin resistance (<I>ob/ob</I> and DIO mice). In <I>ob/ob</I> mice, FGF21 led to a 40&ndash;60% decrease in blood glucose, insulin, and amylin levels within 1 h after injection, and the maximal effects were sustained for more than 6 h despite the 1- to 2-h half-life of FGF21. In DIO mice, FGF21 reduced fasting blood glucose and insulin levels and improved glucose tolerance and insulin sensitivity within 3 h of treatment. The acute improvement of glucose metabolism was associated with a 30% reduction of hepatic glucose production and an increase in peripheral glucose turnover. FGF21 appeared to have no direct effect on ex vivo pancreatic islet insulin or glucagon secretion. However, it rapidly induced typical FGF signaling in liver and adipose tissues and in several hepatoma-derived cell lines and differentiated adipocytes. FGF21 was able to inhibit glucose release from H4IIE hepatoma cells and stimulate glucose uptake in 3T3-L1 adipocytes. We conclude that the acute glucose-lowering and insulin-sensitizing effects of FGF21 are potentially associated with its metabolic actions in liver and adipose tissues.</p>
]]></description>
<dc:creator><![CDATA[Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., Busby, J., Hecht, R., Li, Y.-S., Li, Y., Lindberg, R., Veniant, M. M.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00348.2009</dc:identifier>
<dc:title><![CDATA[Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1114</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1105</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1115?rss=1">
<title><![CDATA[Effects of hormone-sensitive lipase disruption on cardiac energy metabolism in response to fasting and refeeding]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1115?rss=1</link>
<description><![CDATA[
<p>Increased fatty acid (FA) flux and intracellular lipid accumulation (steatosis) give rise to cardiac lipotoxicity in both pathological and physiological conditions. Since hormone-sensitive lipase (HSL) contributes to intracellular lipolysis in adipose tissue and heart, we investigated the impact of HSL disruption on cardiac energy metabolism in response to fasting and refeeding. HSL-knockout (KO) mice and wild-type (WT) littermates were fasted for 24 h, followed by ~6 h of refeeding. Plasma FA concentration in WT mice was elevated twofold with fasting, whereas KO mice lacked this elevation, resulting in twofold lower cardiac FA uptake compared with WT mice. Echocardiography showed that fractional shortening was 15% decreased during fasting in WT mice and was associated with steatosis, whereas both of these changes were absent in KO mice. Compared with Langendorff-perfused hearts isolated from fasted WT mice, the isolated KO hearts also displayed higher contractile function and a blunted response to FA. Although cardiac glucose uptake in KO mice was comparable with WT mice under all conditions tested, cardiac VLDL uptake and lipoprotein lipase (LPL) activity were twofold higher in KO mice during fasting. The KO hearts showed undetectable activity of neutral cholesteryl esterase and 40% lower non-LPL triglyceride lipase activity compared with WT hearts in refed conditions accompanied by overt steatosis, normal cardiac function, and increased mRNA expression of adipose differentiation-related protein. Thus, the dissociation between cardiac steatosis and functional sequelae observed in HSL-KO mice suggests that excess FA influx, rather than steatosis per se, appears to play an important role in the pathogenesis of cardiac lipotoxicity.</p>
]]></description>
<dc:creator><![CDATA[Suzuki, J., Ueno, M., Uno, M., Hirose, Y., Zenimaru, Y., Takahashi, S., Osuga, J.-i., Ishibashi, S., Takahashi, M., Hirose, M., Yamada, M., Kraemer, F. B., Miyamori, I.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.91031.2008</dc:identifier>
<dc:title><![CDATA[Effects of hormone-sensitive lipase disruption on cardiac energy metabolism in response to fasting and refeeding]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1124</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1115</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1125?rss=1">
<title><![CDATA[TIP39/parathyroid hormone type 2 receptor signaling is a potent inhibitor of chondrocyte proliferation and differentiation]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1125?rss=1</link>
<description><![CDATA[
<p>Tuberoinfundibular peptide of 39 residues (TIP39) is a member of the parathyroid hormone (PTH) family of peptide hormones that exerts its function by interacting with the PTH type 2 receptor (PTH2R). Presently, no known function has been attributed to this signaling pathway in the developing skeleton. We observed that TIP39 and PTH2R were present in the newborn mouse growth plate, with the receptor localizing in the resting zone whereas ligand expression was restricted exclusively in prehypertrophic and hypertrophic chondrocytes. By 8 wk of life, PTH2R, and to a lesser degree TIP39, immunoreactivity was present in articular chondrocytes. We therefore sought to investigate the role of TIP39/PTH2R signaling in chondrocytes by generating stably transfected CFK2 chondrocytic cells overexpressing PTH2R (CFK2R). TIP39 treatment of CFK2R clones in culture inhibited their proliferation by restricting cells at the G<SUB>0</SUB>/G<SUB>1</SUB> phase of the cell cycle, coupled with decreased expression and activity of cyclin-dependent kinases Cdk2 and Cdk4, while p21, an inhibitor of Cdks, was upregulated. In addition, TIP39 treatment decreased expression of differentiation markers in these cells associated with marked alterations in extracellular matrix and metalloproteinase expression. Transcription of <I>Sox9</I>, the master regulator of cartilage differentiation, was reduced in TIP39-treated CFK2R clones. Moreover, <I>Sox9</I> promoter activity, as measured by luciferase reporter assay, was markedly diminished after TIP39 treatment. In summary, our results show that TIP39/PTH2R signaling inhibits proliferation and alters differentiation of chondrocytes by modulating SOX9 expression, thereby substantiating the functional significance of this signaling pathway in chondrocyte biology.</p>
]]></description>
<dc:creator><![CDATA[Panda, D., Goltzman, D., Juppner, H., Karaplis, A. C.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00254.2009</dc:identifier>
<dc:title><![CDATA[TIP39/parathyroid hormone type 2 receptor signaling is a potent inhibitor of chondrocyte proliferation and differentiation]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1136</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1125</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1137?rss=1">
<title><![CDATA[Novel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1137?rss=1</link>
<description><![CDATA[
<p>The transcription factor TORC2 [transducer of regulated cAMP-responsive element-binding protein (CREB) activity 2] is a major regulator of hepatic gluconeogenesis and is increased in hyperglycemic rodent models. Because chronic hyperglycemia and increased hepatic glucose production, via increased gluconeogenesis, is a key feature of type 2 diabetes, an effective in vivo method to efficiently knock down TORC2 could provide a potential therapy for treating hyperglycemia and type 2 diabetes. To assess this, primary mouse hepatocytes, high-fat diet (HFD)-fed mice, and Zucker diabetic fatty (ZDF) rats were treated with a siRNA against TORC2 (siTORC2), which was delivered via a novel lipid nanoparticle system, or control siRNA (siCON). Compared with siCON, administration of siTORC2 resulted in highly efficient, sustained (1&ndash;3 wk) knockdown of TORC2 and its gluconeogenic target genes phospho<I>enol</I>pyruvate carboxykinase and glucose-6-phophatase in primary mouse hepatocytes and in the livers of HFD-fed mice. In mice, this knockdown was specific to the liver and did not occur in kidney, skeletal muscle, or adipose tissue. In HFD-fed mice, siTORC2 reduced in vivo gluconeogenic capacity, fasting hepatic glucose production, and hyperglycemia, and led to improved hepatic and skeletal muscle insulin sensitivity. siTORC2 treatment also improved systemic hyperglycemia in ZDF rats. In conclusion, these results demonstrate the importance of TORC2 in modulating HGP in vivo and highlight a novel, liver-specific siRNA approach for the potential treatment of hyperglycemia and type 2 diabetes.</p>
]]></description>
<dc:creator><![CDATA[Saberi, M., Bjelica, D., Schenk, S., Imamura, T., Bandyopadhyay, G., Li, P., Jadhar, V., Vargeese, C., Wang, W., Bowman, K., Zhang, Y., Polisky, B., Olefsky, J. M.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00158.2009</dc:identifier>
<dc:title><![CDATA[Novel liver-specific TORC2 siRNA corrects hyperglycemia in rodent models of type 2 diabetes]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1146</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1137</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1147?rss=1">
<title><![CDATA[Impact of type 1 diabetes on cardiac fibroblast activation: enhanced cell cycle progression and reduced myofibroblast content in diabetic myocardium]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1147?rss=1</link>
<description><![CDATA[
<p>Diabetic patients are prone to developing myocardial fibrosis and suffer from decreased wound healing capabilities. The purpose of this study was to determine whether diabetes alters cardiac fibroblast activity in the myocardium in a 6-wk streptozotocin-induced type 1 diabetic model. In vivo echocardiography indicated significant dilation of the left ventricle (LV) in the diabetic animals, while cardiac function was comparable to that in the normal group. We isolated cardiac fibroblasts from diabetic and control hearts and observed increased proliferation of the diabetic fibroblasts. Microarray analysis using mRNA collected from whole LVs revealed downregulation of known inhibitors of proliferation, p53 and p21, in the diabetic group, consistent with our proliferation data. Western blot analysis confirmed a reduction in p53 protein expression in the diabetic hearts compared with control. We explored the potential signaling underlying the downregulation of these cell cycle mediators and determined that activated Akt, a signal that inhibits p53, was elevated in the diabetic group. Surprisingly, the hearts from the diabetic group contained lower levels of the myofibroblast marker -smooth muscle actin (-SMA) and higher levels of desmin and platelet endothelial cell adhesion molecule (PECAM). The isolated fibroblasts from the diabetic group also contained significantly less -SMA. These data suggest that early-stage diabetic hearts contain highly proliferative fibroblasts, which predisposes the diabetic myocardium to fibrosis, but have fewer myofibroblasts, which may compromise wound healing.</p>
]]></description>
<dc:creator><![CDATA[Shamhart, P. E., Luther, D. J., Hodson, B. R., Koshy, J. C., Ohanyan, V., Meszaros, J. G.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00327.2009</dc:identifier>
<dc:title><![CDATA[Impact of type 1 diabetes on cardiac fibroblast activation: enhanced cell cycle progression and reduced myofibroblast content in diabetic myocardium]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1153</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1147</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1154?rss=1">
<title><![CDATA[Effect of hyperinsulinemia and very-low-calorie diet on interstitial cytokine levels in subcutaneous adipose tissue of obese women]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1154?rss=1</link>
<description><![CDATA[
<p>Type 2 diabetes and obesity are associated with an enhanced release of a number of adipocytokines. Hyperinsulinemia, frequently present in type 2 diabetes and obesity, might be one of the drivers of the enhanced production of adipocytokines. The aim of this study was to investigate the interstitial levels of cytokines in subcutaneous adipose tissue (SCAT) in response to hyperinsulinemia and the effect of weight-reducing hypocaloric diet on this regulation in obese subjects. Thirteen obese premenopausal women participated in the study. Concentrations of seven cytokines were measured in plasma and in AT interstitial fluid collected by microdialysis during a euglycemic-hyperinsulinemic clamp and during control infusion of physiological saline. A subgroup of six women underwent a 4-wk very-low-calorie diet (VLCD). Microdialysis during the clamp was performed before and at the end of VLCD. Hyperinsulinemia induced an increase of monocyte chemoatractant protein (MCP-1) and IL-6 SCAT interstitial and plasma levels and elevated IL-8 levels in SCAT. The relative changes of IL-6 levels in the dialysate correlated with changes of IL-8 and MCP-1. The interstitial and plasma levels of IL-1&beta;, IL-10, TNF, and plasminogen activator inhibitor (PAI-1) remained unchanged in response to hyperinsulinemia. VLCD resulted in enhancement of the hyperinsulinemia-induced augmentation of MCP-1, IL-6, and IL-8 interstitial levels. In conclusion, hyperinsulinemia upregulates the interstitial levels of MCP-1, IL-6, and IL-8 in SCAT in obese women, whereas it does not affect IL-1&beta;, IL-10, TNF, and PAI-1 levels. Hypocaloric diet associated with weight reduction enhances the hyperinsulinemia-induced upregulation of MCP-1, IL-6, and IL-8 in SCAT.</p>
]]></description>
<dc:creator><![CDATA[Siklova-Vitkova, M., Polak, J., Klimcakova, E., Vrzalova, J., Hejnova, J., Kovacikova, M., Kovacova, Z., Bajzova, M., Rossmeislova, L., Hnevkovska, Z., Langin, D., Stich, V.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00086.2009</dc:identifier>
<dc:title><![CDATA[Effect of hyperinsulinemia and very-low-calorie diet on interstitial cytokine levels in subcutaneous adipose tissue of obese women]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1161</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1154</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1162?rss=1">
<title><![CDATA[Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1162?rss=1</link>
<description><![CDATA[
<p>The aim of this study was to investigate the effect of rimonabant treatment on hepatic mitochondrial function in rats fed a high-fat diet. Sprague-Dawley rats fed a high-fat diet (35% lard) for 13 wk were treated with rimonabant (10 mg&middot;kg<sup>&ndash;1</sup>&middot;day<sup>&ndash;1</sup>) during the last 3 wk and matched with pair-fed controls. Oxygen consumption with various substrates, mitochondrial enzyme activities on isolated liver mitochondria, and mitochondrial DNA quantity were determined. Body weight and fat mass were decreased in rats treated with rimonabant compared with pair-fed controls. Moreover, the serum adiponectin level was increased with rimonabant. Hepatic triglyceride content was increased, while serum triglycerides were decreased. An increase of mitochondrial respiration was observed in rats treated with rimonabant. The increase of mitochondrial respiration with palmitoyl-CoA compared with respiration with palmitoyl-<scp>l</scp>-carnitine stating that the entry of fatty acids into mitochondria via carnitine palmitoyltransferase I was increased in rats treated with rimonabant. Moreover, rimonabant treatment led to a reduction in the enzymatic activity of ATP synthase, whereas the quantity of mitochondrial DNA and the activity of citrate synthase remained unchanged. To summarize, rimonabant treatment leads to an improvement of hepatic mitochondrial function by increasing substrate oxidation and fatty acid entry into mitochondria for the &beta;-oxidation pathway and by increasing proton leak. However, this increase of mitochondrial oxidation is regulated by a decrease of ATP synthase activity in order to have only ATP required for the cell function.</p>
]]></description>
<dc:creator><![CDATA[Flamment, M., Gueguen, N., Wetterwald, C., Simard, G., Malthiery, Y., Ducluzeau, P.-H.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:13 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00169.2009</dc:identifier>
<dc:title><![CDATA[Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1170</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1162</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1171?rss=1">
<title><![CDATA[Fetal liver X receptor activation acutely induces lipogenesis but does not affect plasma lipid response to a high-fat diet in adult mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1171?rss=1</link>
<description><![CDATA[
<p>There is increasing evidence that the metabolic state of the mother during pregnancy affects long-term glucose and lipid metabolism of the offspring. The liver X receptors (LXR) and -&beta; are key regulators of cholesterol, fatty acid, and glucose metabolism. LXRs are activated by oxysterols and expressed in fetal mouse liver from <I>day 10</I> of gestation onward. In the present study, we aimed to elucidate whether in utero pharmacological activation of LXR would influence fetal fatty acid and glucose metabolism and whether this would affect lipid homeostasis at adult age. Exposure of pregnant mice to the synthetic LXR agonist T0901317 increased hepatic mRNA expression levels of Lxr target genes and hepatic and plasma triglyceride levels in fetuses and dams. T0901317 treatment increased absolute de novo synthesis and chain elongation of hepatic oleic acid in dams and fetuses. T0901317 exposure in utero influenced lipid metabolism in adulthood in a sex-specific manner; hepatic triglyceride content was increased (+45%) in male offspring and decreased in female offspring (&ndash;42%) when they were fed a regular chow diet compared with untreated sex controls. Plasma and hepatic lipid contents and hepatic gene expression patterns in adult male or female mice fed a high-fat diet were not affected by T0901317 pretreatment. We conclude that LXR treatment of pregnant mice induces immediate effects on lipid metabolism in dams and fetuses. Despite the profound changes during fetal life, long-term effects appeared to be rather mild and sex selective without modulating the lipid response to a high-fat diet.</p>
]]></description>
<dc:creator><![CDATA[van Straten, E. M. E., van Meer, H., Huijkman, N. C. A., van Dijk, T. H., Baller, J. F. W., Verkade, H. J., Kuipers, F., Plosch, T.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:14 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00021.2009</dc:identifier>
<dc:title><![CDATA[Fetal liver X receptor activation acutely induces lipogenesis but does not affect plasma lipid response to a high-fat diet in adult mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1178</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1171</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1179?rss=1">
<title><![CDATA[Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1179?rss=1</link>
<description><![CDATA[
<p>Nonalcoholic fatty liver disease (NAFLD) is an abnormal liver metabolism often observed with insulin resistance and metabolic syndrome. Calorie restriction is a useful treatment for NAFLD and reportedly prolongs the life spans of several species in which sirtuin plays an important role. In this study, we examined whether the activation of SIRT1, a mammalian ortholog of sirtuin, may ameliorate the development of NAFLD. Monosodium glutamate (MSG) mice, which exhibited obesity and insulin resistance, were treated with SRT1720, a specific SIRT1 activator from the age of 6&ndash;16 wk. Sixteen-week-old MSG mice exhibited increased liver triglyceride content and elevated levels of aminotransferase. SRT1720 treatment significantly reduced these levels without affecting body weight or food intake. These results suggested that the administration of SRT1720 ameliorated the development of NAFLD in MSG mice. The expressions of lipogenic genes, such as sterol regulatory element-binding protein-1c, acetyl-CoA carboxylase, and fatty acid synthase, and the serum lipid profiles, including free fatty acids, were elevated in MSG mice and were reduced by SRT1720 treatment. SRT1720 treatment also reduced the expressions of lipogenic genes in cultured HepG2 cells. Furthermore, SRT1720 treatment decreased the expressions of marker genes for oxidative stress and inflammatory cytokines in the liver of MSG mice. Taken together, SRT1720 treatment may reduce liver lipid accumulation, at least in part, by directly reducing the expressions of lipogenic genes. The reduction of oxidative stress and inflammation may also be involved in the amelioration of NAFLD.</p>
]]></description>
<dc:creator><![CDATA[Yamazaki, Y., Usui, I., Kanatani, Y., Matsuya, Y., Tsuneyama, K., Fujisaka, S., Bukhari, A., Suzuki, H., Senda, S., Imanishi, S., Hirata, K., Ishiki, M., Hayashi, R., Urakaze, M., Nemoto, H., Kobayashi, M., Tobe, K.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:14 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90997.2008</dc:identifier>
<dc:title><![CDATA[Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1186</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1179</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1187?rss=1">
<title><![CDATA[Nitric oxides mediates a shift from early necrosis to late apoptosis in cytokine-treated {beta}-cells that is associated with irreversible DNA damage]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1187?rss=1</link>
<description><![CDATA[
<p>For many cell types, including pancreatic &beta;-cells, nitric oxide is a mediator of cell death; however, it is paradoxical that for a given cell type nitric oxide can induce both necrosis and apoptosis. This report tests the hypothesis that cell death mediated by nitric oxide shifts from an early necrotic to a late apoptotic event. Central to this transition is the ability of &beta;-cells to respond and repair nitric oxide-mediated damage. &beta;-Cells have the ability to repair DNA that is damaged following 24-h incubation with IL-1; however, cytokine-induced DNA damage becomes irreversible following 36-h incubation. This irreversible DNA damage following 36-h incubation with IL-1 correlates with the activation of caspase-3 (cleavage and activity). The increase in caspase activity correlates with reductions in endogenous nitric oxide production, as nitric oxide is an inhibitor of caspase activity. In contrast, caspase cleavage or activation is not observed under conditions in which &beta;-cells are capable of repairing damaged DNA (24-h incubation with cytokines). These findings provide evidence that &beta;-cell death in response to cytokines shifts from an early necrotic process to apoptosis and that this shift is associated with irreversible DNA damage and caspase-3 activation.</p>
]]></description>
<dc:creator><![CDATA[Hughes, K. J., Chambers, K. T., Meares, G. P., Corbett, J. A.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:14 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00214.2009</dc:identifier>
<dc:title><![CDATA[Nitric oxides mediates a shift from early necrosis to late apoptosis in cytokine-treated {beta}-cells that is associated with irreversible DNA damage]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1196</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1187</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1197?rss=1">
<title><![CDATA[A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1197?rss=1</link>
<description><![CDATA[
<p>In mice of normal weight and with diet-induced obesity, a high-fat, low-carbohydrate ketogenic diet (KD) causes weight loss, reduced circulating glucose and lipids, and dramatic changes in hepatic gene expression. Many of the effects of KD are mediated by fibroblast growth factor 21 (FGF21). We tested the effects of KD feeding on <I>ob</I>/<I>ob</I> mice to determine if metabolic effects would occur in obesity secondarily to leptin deficiency. We evaluated the effect of prolonged KD feeding on weight, energy homeostasis, circulating metabolites, glucose homeostasis, and gene expression. Subsequently, we evaluated the effects of leptin and fasting on FGF21 expression in <I>ob</I>/<I>ob</I> mice. KD feeding of <I>ob</I>/<I>ob</I> mice normalized fasting glycemia and substantially reduced insulin and lipid levels in the absence of weight loss. KD feeding was associated with significant increases in lipid oxidative genes and reduced expression of lipid synthetic genes, including stearoyl-coenzyme A desaturase 1, but no change in expression of inflammatory markers. In chow-fed <I>ob</I>/<I>ob</I> mice, FGF21 mRNA was elevated 10-fold compared with wild-type animals, and no increase from this elevated baseline was seen with KD feeding. Administration of leptin to chow-fed <I>ob</I>/<I>ob</I> mice led to a 24-fold induction of FGF21. Fasting also induced hepatic FGF21 in <I>ob</I>/<I>ob</I> mice. Thus, KD feeding improved <I>ob</I>/<I>ob</I> mouse glucose homeostasis without weight loss or altered caloric intake. These data demonstrate that manipulation of dietary macronutrient composition can lead to marked improvements in metabolic profile of leptin-deficient obese mice in the absence of weight loss.</p>
]]></description>
<dc:creator><![CDATA[Badman, M. K., Kennedy, A. R., Adams, A. C., Pissios, P., Maratos-Flier, E.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:14 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00357.2009</dc:identifier>
<dc:title><![CDATA[A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1204</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1197</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1205?rss=1">
<title><![CDATA[The effect of high-dose sodium salicylate on chronically elevated plasma nonesterified fatty acid-induced insulin resistance and {beta}-cell dysfunction in overweight and obese nondiabetic men]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1205?rss=1</link>
<description><![CDATA[
<p>Prolonged elevation of plasma nonesterified fatty acids (NEFA) induces insulin resistance and impairs pancreatic &beta;-cell adaptation to insulin resistance. Studies in rodents suggest that inflammation may play a role in this "lipotoxicity." We studied the effects of sodium salicylate, an anti-inflammatory agent, on lipid-induced alterations in &beta;-cell function and insulin sensitivity in six overweight and obese nondiabetic men. Each subject underwent four separate studies, 4&ndash;6 wk apart, in random order: <I>1</I>) SAL, 1-wk placebo followed by intravenous (iv) infusion of saline for 48 h; <I>2</I>) IH, 1-wk placebo followed by iv infusion of intralipid plus heparin for 48 h to raise plasma NEFA approximately twofold; <I>3</I>) IH + SS, 1-wk sodium salicylate (4.5 g/day) followed by 48-h IH infusion; and <I>4</I>) SS, 1-wk oral sodium salicylate followed by 48-h saline infusion. After 48-h saline or lipid infusion, insulin secretion and sensitivity were assessed by hyperglycemic clamp and euglycemic hyperinsulinemic clamp, respectively, in sequential order. Insulin sensitivity was reduced by lipid infusion (IH = 67% of SAL) and was not improved by salicylate (IH + SS = 56% of SAL). Lipid infusion also reduced the disposition index (<I>P</I> &lt; 0.05), which was not prevented by sodium salicylate. Salicylate reduced insulin clearance. These data suggest that oral sodium salicylate at this dose impairs insulin clearance but does not ameliorate lipid-induced insulin resistance and &beta;-cell dysfunction in overweight and obese nondiabetic men.</p>
]]></description>
<dc:creator><![CDATA[Xiao, C., Giacca, A., Lewis, G. F.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:14 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00313.2009</dc:identifier>
<dc:title><![CDATA[The effect of high-dose sodium salicylate on chronically elevated plasma nonesterified fatty acid-induced insulin resistance and {beta}-cell dysfunction in overweight and obese nondiabetic men]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1211</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1205</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1212?rss=1">
<title><![CDATA[Sex differences in the regulation of Kiss1/NKB neurons in juvenile mice: implications for the timing of puberty]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1212?rss=1</link>
<description><![CDATA[
<p>In mammals, puberty onset typically occurs earlier in females than in males, but the explanation for sexual differentiation in the tempo of pubertal development is unknown. Puberty in both sexes is a brain-dependent phenomenon and involves alterations in the sensitivity of neuronal circuits to gonadal steroid feedback as well as gonadal hormone-independent changes in neuronal circuitry. Kisspeptin, encoded by the <I>Kiss1</I> gene, plays an essential but ill-defined role in pubertal maturation. Neurokinin B (NKB) is coexpressed with <I>Kiss1</I> in the arcuate nucleus (ARC) and is also important for puberty. We tested whether sex differences in the timing of pubertal development are attributable to sexual differentiation of gonadal hormone-independent mechanisms regulating hypothalamic <I>Kiss1/NKB</I> gene expression. We found that, in juvenile females, gonadotropin secretion and expression of <I>Kiss1</I> and <I>NKB</I> in the ARC increased immediately following ovariectomy, suggesting that prepubertal females have negligible gonadal hormone-independent restraint on their reproductive axis. In contrast, in similarly aged juvenile males, no changes occurred in LH levels or <I>Kiss1</I> or <I>NKB</I> expression following castration, suggesting that gonadal hormone-independent mechanisms restrain kisspeptin/NKB-dependent activation of the male reproductive axis before puberty. Notably, adult mice of both sexes showed comparable rapid increases in <I>Kiss1/NKB</I> expression and LH secretion following gonadectomy, signifying that sex differences in the regulation of ARC <I>Kiss1/NKB</I> neurons are manifest only during peripubertal development. Our findings demonstrate that the mechanisms controlling pubertal activation of reproduction in mice are different between the sexes and suggest that gonadal hormone-independent central restraint on pubertal timing involves <I>Kiss1/NKB</I> neurons in the ARC.</p>
]]></description>
<dc:creator><![CDATA[Kauffman, A. S., Navarro, V. M., Kim, J., Clifton, D. K., Steiner, R. A.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:14 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00461.2009</dc:identifier>
<dc:title><![CDATA[Sex differences in the regulation of Kiss1/NKB neurons in juvenile mice: implications for the timing of puberty]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1221</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1212</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1222?rss=1">
<title><![CDATA[Castration differentially alters basal and leucine-stimulated tissue protein synthesis in skeletal muscle and adipose tissue]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/297/5/E1222?rss=1</link>
<description><![CDATA[
<p>Reduced testosterone as a result of catabolic illness or aging is associated with loss of muscle and increased adiposity. We hypothesized that these changes in body composition occur because of altered rates of protein synthesis under basal and nutrient-stimulated conditions that are tissue specific. The present study investigated such mechanisms in castrated male rats (75% reduction in testosterone) with demonstrated glucose intolerance. Over 9 wk, castration impaired body weight gain, which resulted from a reduced lean body mass and preferential sparing of adipose tissue. Castration decreased gastrocnemius weight, but this atrophy was not associated with reduced basal muscle protein synthesis or differences in plasma IGF-I, insulin, or individual amino acids. However, oral leucine failed to normally stimulate muscle protein synthesis in castrated rats. In addition, castration-induced atrophy was associated with increased 3-methylhistidine excretion and in vitro-determined ubiquitin proteasome activity in skeletal muscle, changes that were associated with decreased atrogin-1 or MuRF1 mRNA expression. Castration decreased heart and kidney weight without reducing protein synthesis and did not alter either cardiac output or glomerular filtration. In contradistinction, the weight of the retroperitoneal fat depot was increased in castrated rats. This increase was associated with an elevated rate of basal protein synthesis, which was unresponsive to leucine stimulation. Castration also decreased whole body fat oxidation. Castration increased TNF, IL-1, IL-6, and NOS2 mRNA in fat but not muscle. In summary, the castration-induced muscle wasting results from an increased muscle protein breakdown and the inability of leucine to stimulate protein synthesis, whereas the expansion of the retroperitoneal fat depot appears mediated in part by an increased basal rate of protein synthesis-associated increased inflammatory cytokine expression.</p>
]]></description>
<dc:creator><![CDATA[Jiao, Q., Pruznak, A. M., Huber, D., Vary, T. C., Lang, C. H.]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:14 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00473.2009</dc:identifier>
<dc:title><![CDATA[Castration differentially alters basal and leucine-stimulated tissue protein synthesis in skeletal muscle and adipose tissue]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1232</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1222</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/full/297/5/E1233?rss=1">
<title><![CDATA[Corrigendum]]></title>
<link>http://ajpendo.physiology.org/cgi/content/full/297/5/E1233?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 21 Oct 2009 14:10:14 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.zh1-5845-corr.2009</dc:identifier>
<dc:title><![CDATA[Corrigendum]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>E1233</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>E1233</prism:startingPage>
<prism:section>CORRIGENDA</prism:section>
</item>

</rdf:RDF>